Document and Entity Information (USD $)	12 Months Ended
Document and Entity Information (USD $)	Dec. 31, 2014	Jan. 30, 2015	Jun. 30, 2014
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2014
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY
Trading Symbol	MD
Entity Registrant Name	MEDNAX, INC.
Entity Central Index Key	0000893949
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	Yes
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		96,083,342
Entity Public Float			$ 5,710,786,536

Consolidated Balance Sheets (USD $) In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Current assets:
Cash and cash equivalents	$ 47,928	$ 31,137
Short-term investments	6,035	6,457
Accounts receivable, net	352,191	285,397
Prepaid expenses	7,036	6,361
Deferred income taxes	45,961	30,766
Other assets	7,901	8,007
Total current assets	467,052	368,125
Investments	64,082	57,511
Property and equipment, net	66,048	59,911
Goodwill	2,776,188	2,393,731
Other assets, net	235,425	129,438
Total assets	3,608,795	3,008,716
Current liabilities:
Accounts payable and accrued expenses	380,658	308,754
Current portion of long-term debt and capital lease obligations	10,465	92
Income taxes payable	25,150	17,946
Total current liabilities	416,273	326,792
Line of credit	368,000	27,000
Long-term debt and capital lease obligations	190,855	143
Long-term professional liabilities	148,651	139,367
Deferred income taxes	160,487	111,441
Other liabilities	58,963	60,985
Total liabilities	1,343,229	665,728
Commitments and contingencies
Shareholders' equity:
Preferred stock; $.01 par value; 1,000 shares authorized; none issued
Common stock; $.01 par value; 200,000 shares authorized; 96,030 and 101,207 shares issued and outstanding, respectively	960	1,012
Additional paid-in capital	886,877	857,953
Retained earnings	1,376,782	1,484,023
Total MEDNAX, Inc. shareholders' equity	2,264,619	2,342,988
Noncontrolling interests	947
Total equity	2,265,566	2,342,988
Total liabilities and equity	$ 3,608,795	$ 3,008,716

Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, issued	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	96,030,000	101,207,000
Common stock, shares outstanding	96,030,000	101,207,000

Consolidated Statements of Income (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended								12 Months Ended
	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Statement [Abstract]
Net revenue	$ 650,525	$ 626,506	$ 595,544	$ 566,338	$ 567,387	$ 554,730	$ 529,180	$ 502,715	$ 2,438,913	$ 2,154,012	$ 1,816,612
Operating expenses:
Practice salaries and benefits	404,345	394,794	372,216	372,040	353,316	346,879	331,922	329,201	1,543,395	1,361,318	1,130,913
Practice supplies and other operating expenses	23,549	21,570	22,466	21,417	24,027	19,445	19,416	19,500	89,002	82,388	71,823
General and administrative expenses	67,641	60,643	60,829	58,414	55,636	54,654	54,601	53,318	247,527	218,209	193,540
Depreciation and amortization	13,903	11,356	10,361	10,370	10,491	10,461	9,870	9,144	45,990	39,966	30,816
Total operating expenses	509,438	488,363	465,872	462,241	443,470	431,439	415,809	411,163	1,925,914	1,701,881	1,427,092
Income from operations	141,087	138,143	129,672	104,097	123,917	123,291	113,371	91,552	512,999	452,131	389,520
Investment income	195	563	335	1,635	526	372	396	402	2,728	1,696	1,896
Interest expense	(3,313)	(2,019)	(2,188)	(1,371)	(1,046)	(1,507)	(1,673)	(1,189)	(8,891)	(5,415)	(3,245)
Equity in earnings of unconsolidated affiliate	905	725	150						1,780
Total non-operating expenses	(2,213)	(731)	(1,703)	264					(4,383)	(3,719)	(1,349)
Income before income taxes	138,874	137,412	127,969	104,361	123,397	122,156	112,094	90,765	508,616	448,412	388,171
Income tax provision	50,594	51,174	48,944	40,701	44,423	45,198	42,876	35,398	191,413	167,895	147,264
Net income	88,280	86,238	79,025	63,660					317,203	280,517	240,907
Net loss attributable to noncontrolling interests	118	(31)	(9)						78
Net income attributable to MEDNAX, Inc.	$ 88,398	$ 86,207	$ 79,016	$ 63,660	$ 78,974	$ 76,958	$ 69,218	$ 55,367	$ 317,281	$ 280,517	$ 240,907
Net income attributable to MEDNAX, Inc.:
Earnings per share, Basic	$ 0.90	$ 0.87	$ 0.80	$ 0.64	$ 0.79	$ 0.77	$ 0.70	$ 0.56	$ 3.22	$ 2.83	$ 2.47
Earnings per share, Diluted	$ 0.89	$ 0.86	$ 0.79	$ 0.63	$ 0.78	$ 0.76	$ 0.68	$ 0.55	$ 3.18	$ 2.78	$ 2.42
Weighted average common shares:
Basic	98,066	99,088	98,411	99,076	99,469	99,506	99,116	98,618	98,588	99,112	97,386
Diluted	99,129	100,145	99,866	100,696	101,080	101,178	101,098	100,784	99,887	100,969	99,382

Consolidated Statements of Equity (USD $) In Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Noncontrolling Interests [Member]
Balance at Dec. 31, 2011	$ 1,731,016	$ 978	$ 724,157	$ 1,005,881
Balance, Shares at Dec. 31, 2011		97,866
Net income (loss)	240,907			240,907
Common stock issued under employee stock option and stock purchase plan	28,810	13	28,797
Common stock issued under employee stock option and stock purchase plan, shares		1,320
Issuance of restricted stock and vesting of deferred stock		9	(9)
Issuance of restricted stock and vesting of deferred stock, shares		930
Stock-based compensation expense	28,437		28,437
Forfeitures of restricted stock	0
Forfeitures of restricted stock, shares		(78)
Excess tax benefit related to employee stock incentive plans	6,198		6,198
Balance at Dec. 31, 2012	2,035,368	1,000	787,580	1,246,788
Balance, Shares at Dec. 31, 2012		100,038
Net income (loss)	280,517			280,517
Common stock issued under employee stock option and stock purchase plan	28,697	14	28,683
Common stock issued under employee stock option and stock purchase plan, shares		1,331
Issuance of restricted stock and vesting of deferred stock		9	(9)
Issuance of restricted stock and vesting of deferred stock, shares		922
Stock-based compensation expense	31,288		31,288
Forfeitures of restricted stock	0
Forfeitures of restricted stock, shares		(28)
Repurchased common stock	(51,863)	(11)	(8,570)	(43,282)
Repurchased common stock, shares		(1,056)
Excess tax benefit related to employee stock incentive plans	18,981		18,981
Balance at Dec. 31, 2013	2,342,988	1,012	857,953	1,484,023
Balance, Shares at Dec. 31, 2013		101,207
Contributions from noncontrolling interests	1,025				1,025
Net income (loss)	317,203			317,281	(78)
Common stock issued under employee stock option and stock purchase plan	42,876	13	42,863
Common stock issued under employee stock option and stock purchase plan, shares		1,412
Issuance of restricted stock and vesting of deferred stock		6	(6)
Issuance of restricted stock and vesting of deferred stock, shares		573
Issuance of restricted stock for contingent consideration	705		705
Issuance of restricted stock for contingent consideration, shares		12
Stock-based compensation expense	31,719		31,719
Forfeitures of restricted stock	0
Forfeitures of restricted stock, shares		(34)
Repurchased common stock	(488,429)	(71)	(63,836)	(424,522)
Repurchased common stock, shares		(7,140)
Excess tax benefit related to employee stock incentive plans	17,479		17,479
Balance at Dec. 31, 2014	$ 2,265,566	$ 960	$ 886,877	$ 1,376,782	$ 947
Balance, Shares at Dec. 31, 2014		96,030

Consolidated Statements of Cash Flows (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Cash flows from operating activities:
Net income	$ 317,203	$ 280,517	$ 240,907
Adjustments to reconcile net income to net cash provided from operating activities:
Depreciation and amortization	45,990	39,966	30,816
Net change in fair value of contingent consideration liabilities	(417)	3,656	995
Stock-based compensation expense	31,719	31,288	28,437
Equity in earnings of unconsolidated affiliate	(1,780)
Deferred income taxes	2,559	15,920	21,344
Changes in assets and liabilities:
Accounts receivable	(57,018)	(37,331)	(17,678)
Prepaid expenses and other assets	1,506	212	(244)
Other assets	2,137	(3,541)	1,153
Accounts payable and accrued expenses	66,039	49,239	16,953
Income taxes payable	6,998	5,772	(7,343)
Payments of contingent consideration liabilities	(4,071)	(1,308)	(786)
Long-term professional liabilities	9,284	19,797	9,941
Other liabilities	2,492	1,211	411
Net cash provided from operating activities	422,641	405,398	324,906
Cash flows from investing activities:
Acquisition payments, net of cash acquired	(479,394)	(238,045)	(441,006)
Purchases of investments	(26,884)	(20,802)	(33,120)
Proceeds from sales or maturities of investments	20,735	11,011	28,073
Purchases of property and equipment	(18,061)	(15,654)	(14,495)
Net cash used in investing activities	(503,604)	(263,490)	(460,548)
Cash flows from financing activities:
Borrowings on credit facility	1,754,500	911,500	517,500
Payments on credit facility	(1,213,500)	(1,028,500)	(402,500)
Payments for credit facility financing costs	(4,281)		(2,397)
Payments of contingent consideration liabilities	(11,740)	(10,365)	(9,445)
Payments on capital lease obligations	(159)	(99)	(136)
Excess tax benefit from exercises of stock options and vesting of restricted and deferred stock	17,462	18,579	6,494
Proceeds from issuance of common stock	42,876	28,697	28,810
Contribution from noncontrolling interests	1,025
Repurchases of common stock	(488,429)	(51,863)
Net cash provided from (used in) financing activities	97,754	(132,051)	138,326
Net increase in cash and cash equivalents	16,791	9,857	2,684
Cash and cash equivalents at beginning of year	31,137	21,280	18,596
Cash and cash equivalents at end of year	47,928	31,137	21,280
Supplemental disclosure of cash flow information:
Interest	7,323	3,312	2,044
Income taxes	161,841	126,411	129,636
Non-cash financing activities:
Equipment financed through capital leases	$ 1,244

General	12 Months Ended
General	Dec. 31, 2014
Accounting Policies [Abstract]
General	1. General: The principal business activity of MEDNAX, Inc. (“MEDNAX” or the “Company”) and its subsidiaries is to provide neonatal, anesthesia, maternal-fetal and other pediatric subspecialties physician services. The Company has contracts with affiliated business corporations or professional associations, limited liability companies and partnerships (“affiliated professional contractors”), which are separate legal entities that provide physician services in certain states and Puerto Rico. The Company and its affiliated professional contractors also have contracts with hospitals and other healthcare facilities to provide physician services, which include (i) fee-for-service contracts, whereby hospitals agree, in exchange for the Company’s services, to authorize the Company and its healthcare professionals to bill and collect the charges for medical services rendered by the Company’s affiliated healthcare professionals, and (ii) administrative fee contracts, whereby the Company is assured a minimum revenue level. In addition to the Company’s national physician network, during 2014 the Company acquired two complementary businesses that offer services to medical providers, including its own, consisting of a revenue cycle management company and a consulting services company. The Company expects that the development of these service offerings will function as support for its own physician practices as well as an outsourced services capability.

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2014

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

2. Summary of Significant Accounting Policies:

Principles of Presentation

The financial statements include all the accounts of the Company and its subsidiaries combined with the accounts of the affiliated professional contractors with which the Company currently has specific management arrangements. The Company’s agreements with affiliated professional contractors provide that the term of the arrangements are in most cases permanent, subject only to termination by the Company, except in the case of gross negligence, fraud or bankruptcy of the Company. The Company has the right to receive income, both as ongoing fees and as proceeds from the sale of its interest in the Company’s affiliated professional contractors, in an amount that fluctuates based on the performance of the affiliated professional contractors and the change in the fair value of the Company’s interest in the affiliated professional contractors. The Company has exclusive responsibility for the provision of all non-medical services required for the day-to-day operation and management of the Company’s affiliated professional contractors and establishes the guidelines for the employment and compensation of the physicians. In addition, the agreements provide that the Company has the right, but not the obligation, to purchase, or to designate a person(s) to purchase, the stock of the Company’s affiliated professional contractors for a nominal amount. Separately, in its sole discretion, the Company has the right to assign its interest in the agreements. Based upon the provisions of these agreements, the Company has determined that the affiliated professional contractors are variable interest entities and that the Company is the primary beneficiary as defined in the accounting guidance for consolidation. All significant intercompany and interaffiliate accounts and transactions have been eliminated.

On June 1, 2014, the Company entered into a joint venture in which it owns a 75% economic interest. The Company has a management agreement with the joint venture and, based on the terms of the agreement, the Company has determined that the joint venture is a variable interest entity for which the Company is the primary beneficiary as defined in the accounting guidance for consolidation. Accordingly, the financial results of the joint venture are fully consolidated into the Company’s operating results. The equity interests of the outside investor in the equity and results of operations of this consolidated entity are accounted for and presented as noncontrolling interests. Also on June 1, 2014, the Company entered into a second joint venture in which it owns a 37.5% economic interest. The Company accounts for this joint venture under the equity method of accounting because the Company exercises significant influence over, but does not control, this entity.

Reclassifications have been made to certain prior period financial statements to conform with the current year presentation. Specifically, the Company reclassified $40.7 million of its deferred tax assets as of December 31, 2013 from current deferred income taxes to long-term deferred income taxes. This revision represents the correction of an error in the classification of certain deferred tax assets in our prior period Consolidated Financial Statements that the Company has determined to be immaterial.

All share and per share data set forth herein give effect to the two-for-one split of the Company’s common stock that became effective on December 19, 2013.

New Accounting Pronouncements

In May 2014, the accounting guidance related to revenue recognition was amended to outline a single, comprehensive model for accounting for revenue from contracts with customers. While the new guidance supersedes existing revenue recognition guidance, it closely aligns with current accounting principles generally accepted in the United States of America (“GAAP”). The new guidance will become effective for the Company on January 1, 2017, and early adoption is not permitted. The Company is currently evaluating the impact, if any, the adoption of this guidance will have on the Company’s Consolidated Financial Statements.

Accounting Estimates and Assumptions

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Significant estimates and assumptions are involved in the calculation of the Company’s allowance for contractual adjustments and uncollectibles on accounts receivable, liabilities for self-insured amounts and claims incurred but not reported related to the Company’s professional liability risks, the fair value of goodwill, and liabilities for uncertain tax positions. Actual results could differ from those estimates.

Segment Reporting

The results of the Company’s operations are aggregated into a single reportable segment for purposes of presenting financial information in accordance with the accounting guidance for segment reporting.

The following table summarizes the Company’s net revenue by specialties and subspecialties (in percentages):


	Years Ended December 31,
	2014			2013			2012
Neonatal and other pediatric subspecialties		50	%		52	%		56	%
Anesthesia		36	%		32	%		27	%
Maternal-fetal		9	%		11	%		12	%
Pediatric cardiology		4	%		5	%		5	%
Other services		1	%		—			—

		100	%		100	%		100	%

Revenue Recognition

Patient service revenue is recognized at the time services are provided by the Company’s affiliated physicians. Almost all of the Company’s patient service revenue is reimbursed by government-sponsored healthcare programs and third-party insurance payors. Payments for services rendered to the Company’s patients are generally less than billed charges. The Company monitors its revenue and receivables from these sources and records an estimated contractual allowance to properly account for the anticipated differences between billed and reimbursed amounts.

Accordingly, patient service revenue is presented net of an estimated provision for contractual adjustments and uncollectibles. The Company estimates allowances for contractual adjustments and uncollectibles on accounts receivable based upon historical experience and other factors, including days sales outstanding (“DSO”) for accounts receivable, evaluation of expected adjustments and delinquency rates, past adjustments and collection experience in relation to amounts billed, an aging of accounts receivable, current contract and reimbursement terms, changes in payor mix and other relevant information. Contractual adjustments result from the difference between the physician rates for services performed and the reimbursements by government-sponsored healthcare programs and insurance companies for such services.

In addition, the Company generates non-practice revenue for services rendered under various coding and billing contracts. Contract terms are specific to each customer and may include a combination of a flat fee for coding of medical charts, a fixed fee per patient visit as well as a percentage of cash collections received by the providers. Revenue for flat and fixed fee arrangements is recognized in the month the coding occurs or the patient visit occurs. Revenue for percentage fees are recognized in the month that cash is collected for customers from payors. Revenue recorded for these services during 2014 were immaterial.

Accounts receivable are primarily amounts due under fee-for-service contracts from third-party payors, such as insurance companies, self-insured employers and patients and government-sponsored healthcare programs geographically dispersed throughout the United States and its territories. Concentration of credit risk relating to accounts receivable is limited by the number, diversity and geographic dispersion of the business units managed by the Company, as well as by the large number of patients and payors, including the various governmental agencies in the states in which the Company provides services. Receivables from government agencies made up approximately 20% of net accounts receivable at December 31, 2014 and 2013.

Cash Equivalents

Cash equivalents are defined as all highly liquid financial instruments with maturities of 90 days or less from the date of purchase. The Company’s cash equivalents typically consist of demand deposits, amounts on deposit in money market accounts, and funds invested in overnight repurchase agreements. Cash equivalent balances may, at certain times, exceed federally insured limits.

Certain cash equivalents carried by the Company are subject to the fair value provisions of the accounting guidance for fair value measurements. See “Fair Value Measurements” below.

Investments

Investments consist of municipal debt securities, federal home loan securities and certificates of deposit. Investments with remaining maturities of less than one year are classified as short-term investments. Investments classified as long-term have maturities of one year to seven years.

The Company intends and has the ability to hold its held-to-maturity securities to maturity, and therefore carries such investments at amortized cost in accordance with the provisions of the accounting guidance for investments in debt and equity securities.

Property and Equipment

Property and equipment are recorded at original purchase cost. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the underlying assets. Estimated useful lives are generally 20 years for buildings; three to 10 years for medical equipment, computer equipment, software and furniture; and the lesser of the useful life or the remaining lease term for leasehold improvements and capital leases. Upon sale or retirement of property and equipment, the related cost and accumulated depreciation are eliminated from the respective accounts and any resulting gain or loss is included in earnings.

Business Acquisitions

The Company accounts for business acquisitions as required by the provisions of the accounting guidance for business combinations such that all business combinations are required to be accounted for at fair value. The guidance requires the Company to expense certain acquisition costs as they are incurred. In accordance with the acquisition method of accounting, any identifiable assets acquired and any liabilities assumed are recognized and measured at their fair values on the acquisition date. If information about facts and circumstances existing as of the acquisition date is incomplete at the end of the reporting period in which a business acquisition occurs, the Company will report provisional amounts for the items for which the accounting is incomplete. The measurement period ends once the Company receives sufficient information to finalize the fair values; however, the period will not exceed one year from the acquisition date. Any material adjustments recognized during the measurement period will be reflected retrospectively in the Consolidated Financial Statements of the subsequent period.

In connection with certain acquisitions, the Company enters into agreements to pay additional amounts in cash or common stock based on the achievement of certain performance measures for up to five years ending after the acquisition dates. The Company measures this contingent consideration at fair value at the acquisition date and records such contingent consideration as a liability or equity on the Company’s Consolidated Balance Sheet on the acquisition date. The fair value of each contingent consideration liability is remeasured at each reporting period with any change in fair value recognized as income or expense within operations in the Company’s Consolidated Statements of Income. See Note 6 for more information on the Company’s business acquisitions.

Goodwill and Other Intangible Assets

The Company records acquired assets and liabilities at their respective fair values under the acquisition method of accounting. Goodwill represents the excess of cost over the fair value of the net assets acquired. Intangible assets with finite lives, principally physician and hospital agreements, customer relationships and trade names, are recognized apart from goodwill at the time of acquisition based on the contractual-legal and separability criteria established in the accounting guidance for business combinations. Intangible assets with finite lives are amortized on either an accelerated basis based on the annual undiscounted economic cash flows associated with the particular intangible asset or on a straight-line basis over their estimated useful lives. Intangible assets with finite lives are amortized over periods of one to 20 years.

Goodwill is tested for impairment at a reporting unit level on at least an annual basis in accordance with the subsequent measurement provisions of the accounting guidance for goodwill. The Company defines a reporting unit based upon its management structure for services provided in specific regions of the United States. The testing for impairment is completed using a two-step test. The first step compares the fair value of a reporting unit with its carrying amount, including goodwill. If the carrying amount of a reporting unit exceeds its fair value, a second step is performed to determine the amount of any impairment loss. The Company uses income and market-based valuation approaches to determine the fair value of its reporting units. These approaches focus on discounted cash flows and market multiples based on the Company’s market capitalization to derive the fair value of a reporting unit. The Company also considers the economic outlook for the healthcare services industry and various other factors during the testing process, including hospital and physician contract changes, local market developments, changes in third-party payor payments, and other publicly available information. The Company completed annual impairment tests in the third quarter of each of 2014, 2013 and 2012 and determined that goodwill was not impaired in any of the three years.

Long-Lived Assets

The Company is required to evaluate long-lived assets, including intangible assets subject to amortization, whenever events or changes in circumstances indicate that the carrying value of the assets may not be fully recoverable. The recoverability of such assets is measured by a comparison of the carrying value of the assets to the future undiscounted cash flows before interest charges to be generated by the assets. If long-lived assets are impaired, the impairment to be recognized is measured as the excess of the carrying value over the fair value. Long-lived assets held for disposal are reported at the lower of the carrying value or fair value less disposal costs. The Company does not believe there are any indicators that would require an adjustment to such assets or their estimated periods of recovery at December 31, 2014 pursuant to current accounting standards.

Common Stock Repurchases

The Company repurchases shares of its common stock as authorized from time to time by its Board of Directors. The Company treats repurchased shares of its common stock as authorized but unissued shares. The reacquisition cost of repurchased shares is recorded as a reduction in the respective components of shareholders’ equity.

Professional Liability Coverage

The Company maintains professional liability insurance policies with third-party insurers generally on a claims-made basis, subject to self-insured retention, exclusions and other restrictions. The Company’s self-insured retention under its professional liability insurance program is maintained primarily through a wholly owned captive insurance subsidiary. The Company records an estimate of liabilities for self-insured amounts and claims incurred but not reported based on an actuarial valuation using historical loss information, claim emergence patterns and various actuarial assumptions. Liabilities for claims incurred but not reported are not discounted.

Income Taxes

The Company records deferred income taxes using the liability method, whereby deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.

The accounting guidance for uncertain tax positions prescribes a recognition threshold and measurement attribute for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The guidance also requires policy disclosures regarding penalties and interest and extensive disclosures regarding increases and decreases in uncertain tax positions as a result of tax positions taken in a current or prior period, settlements with taxing authorities and any lapse of an applicable statute of limitations. Additional qualitative discussion is required for any tax position that may result in a significant increase or decrease in uncertain tax positions within a 12-month period from the Company’s reporting date.

Stock Incentive Plans

The Company grants stock-based awards consisting primarily of restricted and deferred stock to key employees under its Amended and Restated 2008 Incentive Compensation Plan. In accordance with the accounting guidance for stock-based compensation, the Company measures the cost of employee services received in exchange for stock-based awards based on grant-date fair value and allocates the resulting compensation expense over the corresponding requisite service period using the graded vesting attribution method. The Company also performs analyses to estimate forfeitures of stock-based awards as required by the accounting guidance for stock-based compensation. The Company is required to assess its forfeiture estimates on at least an annual basis and adjust the estimates as necessary based on the number of awards that ultimately vest.

Net Income Per Common Share

Basic net income per common share is calculated by dividing net income by the weighted average number of common shares outstanding during the period. Diluted net income per common share is calculated by dividing net income by the weighted average number of common and potential common shares outstanding during the period. Potential common shares consist of outstanding restricted and deferred stock and stock options calculated using the treasury stock method. Under the treasury stock method, the Company includes the assumed excess tax benefits related to the potential exercise or vesting of its stock-based awards using the difference between the average market price for the applicable period less the option price, if any, and the fair value of the stock-based award on the date of grant multiplied by the applicable tax rate.

Fair Value Measurements

In accordance with the accounting guidance for fair value measurements and disclosures, the Company carries its money market funds included in cash and cash equivalents at fair value. In accordance with the three-tier fair value hierarchy under this guidance, the Company determined the fair value using quoted market prices, a Level 1 input as defined under the accounting guidance for fair value measurements. At December 31, 2014 and 2013, the Company’s money market funds had a carrying amount of $5.1 million and $5.3 million, respectively.

The Company also carries the cash surrender value of life insurance related to its deferred compensation arrangements at fair value. The investments underlying the life insurance contracts consist primarily of exchange-traded equity securities and mutual funds with quoted prices in active markets. In accordance with the three-tier fair value hierarchy, the Company determined the fair value using the cash surrender value of the life insurance, a Level 2 input as defined under the accounting guidance for fair value measurements. At December 31, 2014 and 2013, the Company’s cash surrender value of life insurance had a carrying amount of $16.0 million and $17.1 million, respectively.

In addition, the Company carries its contingent consideration liabilities related to acquisitions at fair value. In accordance with the three-tier fair value hierarchy, the Company determined the fair value of its contingent consideration liabilities using the income approach with assumed discount rates and payment probabilities. The income approach uses Level 3, or unobservable inputs as defined under the accounting guidance for fair value measurements. At December 31, 2014 and 2013, the Company’s contingent consideration liabilities had a fair value of $35.3 million and $43.0 million, respectively. See Note 6 for more information regarding the Company’s contingent consideration liabilities.

The carrying amounts of cash equivalents, short-term investments, accounts receivable and accounts payable and accrued expenses approximate fair value due to the short maturities of the respective instruments. The carrying values of long-term investments, line of credit, long-term debt and capital lease obligations approximate fair value. If the Company’s line of credit and long-term debt were measured at fair value, they would be categorized as Level 2 in the fair value hierarchy.

- Definition

The entire disclosure for all significant accounting policies of the reporting entity.

+ References+ Details

Investments

12 Months Ended

Dec. 31, 2014

Investments, Debt and Equity Securities [Abstract]

Investments

3. Investments:

Investments held are summarized as follows (in thousands):


	December 31, 2014				December 31, 2013
	Short-Term		Long-Term		Short-Term		Long-Term
Municipal debt securities	$	5,539	$	35,827	$	5,492	$	34,495
Federal home loan securities		—		27,030		—		22,520
Certificates of deposit		496		1,225		965		496

	$	6,035	$	64,082	$	6,457	$	57,511

Contractual maturities of long-term investments are summarized as follows (in thousands):


	December 31,
	2014		2013
Due after one year through five years	$	54,959	$	41,655
Due after five years through seven years		9,123		15,856

	$	64,082	$	57,511

- Definition

The entire disclosure for investments in certain debt and equity securities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27290-111563

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27357-111563

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-Glossary Debt Security

-URI http://asc.fasb.org/extlink&oid=6509901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6379141&loc=d3e15032-111544

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27232-111563

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 320

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6957658&loc=d3e62557-112803

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27161-111563

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27405-111563

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-Glossary Equity Security

-URI http://asc.fasb.org/extlink&oid=6511694

+ Details

Accounts Receivable and Net Revenue

12 Months Ended

Dec. 31, 2014

Text Block [Abstract]

Accounts Receivable and Net Revenue

4. Accounts Receivable and Net Revenue:

Accounts receivable, net consists of the following (in thousands):


	December 31,
	2014			2013
Gross accounts receivable	$	1,200,958		$	997,682
Allowance for contractual adjustments and uncollectibles		(848,767	)		(712,285)

	$	352,191		$	285,397

Net revenue consists of the following (in thousands):


	Years Ended December 31,
	2014			2013			2012
Gross revenue	$	7,662,556		$	6,702,484		$	5,691,790
Contractual adjustments and uncollectibles		(5,403,437	)		(4,695,232	)		(3,994,924	)
Hospital contract administrative fees		179,794			146,760			119,746

	$	2,438,913		$	2,154,012		$	1,816,612

Accounts receivable of $352.2 million and $285.4 million at December 31, 2014 and 2013, respectively, consist primarily of amounts due from government-sponsored healthcare programs and third-party insurance payors for services provided by the Company’s affiliated physicians.

Net revenue of $2.4 billion, $2.2 billion and $1.8 billion for the years ended December 31, 2014, 2013 and 2012, respectively, consists primarily of gross billed charges for services provided by the Company’s affiliated physicians less an estimated allowance for contractual adjustments and uncollectibles to properly account for the anticipated differences between gross billed charge amounts and expected reimbursement amounts.

The Company’s contractual adjustments and uncollectibles as a percentage of gross patient service revenue vary slightly each year depending on several factors, including improved managed care contracting, changes in reimbursement from state Medicaid programs and other government-sponsored programs, shifts in the percentage of patient services being reimbursed under government-sponsored programs and annual price increases.

The Company’s annual price increases typically increase contractual adjustments as a percentage of gross patient service revenue. This increase is primarily due to Medicaid and other government-sponsored health care programs that generally provide for reimbursements on a fee-schedule basis rather than on a gross charge basis. When the Company bills these programs, like other payors, on a gross-charge basis, it also increases its provision for contractual adjustments and uncollectibles by the amount of any price increase, resulting in a higher contractual adjustment percentage.

Property and Equipment

12 Months Ended

Dec. 31, 2014

Property, Plant and Equipment [Abstract]

Property and Equipment

5. Property and Equipment:

Property and equipment consists of the following (in thousands):


	December 31,
	2014			2013
Building	$	22,981		$	22,981
Land		6,683			6,683
Equipment and other		133,279			117,246

		162,943			146,910
Accumulated depreciation		(96,895	)		(86,999	)

	$	66,048		$	59,911

At December 31, 2014 and 2013, property and equipment includes medical and other equipment held under capital leases of approximately $2.4 million and $1.4 million, and related accumulated depreciation of approximately $1.4 million and $1.2 million, respectively. The Company recorded depreciation expense of approximately $15.9 million, $15.5 million and $15.8 million for the years ended December 31, 2014, 2013 and 2012, respectively.

- Definition

The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.

+ References+ Details

Business Acquisitions

12 Months Ended

Dec. 31, 2014

Business Combinations [Abstract]

Business Acquisitions

6. Business Acquisitions:

During 2014, the Company completed 13 acquisitions, composed of 11 physician group practices, a complementary revenue cycle management company as well as a consulting services company for total consideration of $488.6 million, consisting of $479.4 million in cash and $9.2 million of contingent consideration.

The Company’s allocation of purchase price is as follows:


Current assets	$	11.8
Property and equipment		3.8
Goodwill		389.6
Other intangible assets		124.8
Current liabilities		(14.4	)
Deferred income tax liabilities—long-term		(26.3	)
Other long-term liabilities		(0.7	)

	$	488.6

The physician practice acquisitions expanded the Company’s national network of physician practices. The Company expects to improve the results of these physician practices through improved managed care contracting, improved collections, identification of growth initiatives, as well as, operating and cost savings based upon the significant infrastructure it has developed. The acquisitions of the complementary services businesses establish service offerings that the Company expects will function as support for its own physician practices as well as a revenue generating outsourced services capability.

The contingent consideration of $9.2 million recorded during 2014 is related to agreements to pay additional amounts, based on the achievement of certain performance measures for up to five years ending after the acquisition dates. Potential payments under these provisions are not contingent upon the future employment of the sellers. Approximately $8.5 million of the contingent consideration was recorded as a liability and approximately $0.7 million was recorded as equity, all at acquisition-date fair value. The liability for contingent consideration was recorded using the income approach with assumed discount rates ranging from 2.5% to 5.3% over the applicable terms and an assumed payment probability of 100% for each of the applicable years. The range of the undiscounted amount the Company could pay under the contingent consideration agreements that were recorded with a fair value of $9.2 million is between $0 and $10.3 million. In addition, during 2014, the Company recorded a decrease to its contingent consideration liability of $1.6 million related to the change in fair value of certain contingent consideration agreements for which the performance measures will not be met. This change in fair value was recorded within operating income.

During 2014, the Company paid approximately $15.8 million for contingent consideration related to certain prior-period acquisitions, of which all but the accretion recorded during 2014 was accrued as of December 31, 2013.

Under all contingent consideration provisions, cash payments of up to $37.5 million may be due through 2019, of which $35.3 million is accrued as of December 31, 2014 with the remainder representing accretion that will be recorded through the respective dates of payment.

On June 1, 2014, the Company entered into two joint ventures, one in which it owns a 75% economic interest and one in which it owns a 37.5% economic interest. The financial results of the 75% owned joint venture are fully consolidated into the Company’s operating results and are not material to the Consolidated Financial Statements. In connection with the 37.5% owned joint venture, the Company completed a nonmonetary exchange of certain operations with a fair value of $7.7 million as contribution to the joint venture. The carrying value of the goodwill transferred of $7.2 million and the fixed assets transferred of $0.5 million approximated the fair value of the contribution to this joint venture, and accordingly no gain or loss was recognized on the transaction. The investment in this joint venture is included in other assets, net as presented in the Company’s Consolidated Balance Sheet.

During 2013, the Company completed the acquisition of 11 physician group practices for total consideration of $250.1 million, consisting of $236.7 million in cash and $13.4 million of contingent consideration. In connection with these acquisitions, the Company recorded goodwill of approximately $228.6 million, other intangible assets consisting primarily of physician and hospital agreements of approximately $29.6 million, and other liabilities of approximately $8.1 million.

The results of operations of the practices acquired in 2014 and 2013 have been included in the Company’s Consolidated Financial Statements from the dates of acquisition. The following unaudited pro forma information combines the consolidated results of operations of the Company on a GAAP basis and the acquisitions completed during 2014 and 2013, including adjustments for pro forma amortization and interest expense, as if the transactions had occurred on January 1, 2013 and January 1, 2012, respectively (in thousands, except per share data):


	Years Ended December 31,
	2014		2013
Net revenue	$	2,590,384	$	2,494,968
Net income		326,216		301,076
Net income per common share (1):
Basic	$	3.31	$	3.04
Diluted	$	3.27	$	2.98
Weighted average common shares (1):
Basic		98,588		99,112
Diluted		99,887		100,969

(1)	The comparison of net income per common share is affected by the changes in the number of weighted average shares outstanding in each period.

The pro forma results do not necessarily represent results which would have occurred if the acquisitions had taken place at the beginning of the periods indicated, nor are they indicative of the results of future combined operations.

- Definition

The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6996-128479

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7000-128479

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4922-128472

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4926-128472

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4934-128472

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1383-128463

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1392-128463

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1486-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1497-128463

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1490-128463

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4845-128472

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1500-128463

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 7

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1524-128463

+ Details

Goodwill and Other Assets

12 Months Ended

Dec. 31, 2014

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Other Assets

7. Goodwill and Other Assets:

Goodwill was $2.8 billion and $2.4 billion at December 31, 2014 and 2013, respectively. The change in the carrying amount of goodwill of approximately $382.5 million during the year ended December 31, 2014 is primarily related to the Company’s 2014 acquisitions. The Company expects that approximately $229.3 million of the goodwill recorded during the year ended December 31, 2014 will be deductible for tax purposes. The change in the carrying amount of goodwill during the year ended December 31, 2013 of approximately $228.1 million related to the 2013 acquisitions.

Other assets consist of the following (in thousands):


	December 31,
	2014		2013
Other intangible assets, net	$	198,136	$	103,639
Other assets		37,289		25,799

	$	235,425	$	129,438

At December 31, 2014, other intangible assets consisted of amortizable hospital and other contracts, physician and hospital agreements, customer relationships and trade names with gross carrying amounts of approximately $299.0 million, less accumulated amortization of approximately $100.9 million. The customer relationships and trade names are related to the complementary revenue cycle management company acquired during 2014. At December 31, 2013, other intangible assets consisted of amortizable hospital and other contracts and physician and hospital agreements with gross carrying amounts of approximately $174.4 million, less accumulated amortization of approximately $70.8 million.

Amortization expense for existing other intangible assets was $30.1 million, $24.5 million and $15.0 million for the years ended December 31, 2014, 2013 and 2012, respectively.

Amortization expense for existing other intangible assets for the next five years is expected to be as follows (in thousands):


2015	$	36,874
2016		30,985
2017		24,919
2018		20,190
2019		16,059

The remaining weighted average amortization period of other intangible assets is 8.7 years. The calculation of the weighted average amortization period includes amortization expense related to years beyond 2019 of approximately $69.1 million.

Other assets of $37.3 million and $25.8 million at December 31, 2014 and 2013, respectively, consist primarily of the cash surrender value of life insurance related to the Company’s deferred compensation arrangements of $16.0 million and $17.1 million, respectively, and at December 31, 2014 also includes the Company’s investment in a joint venture of $9.5 million.

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References+ Details

Accounts Payable and Accrued Expenses

12 Months Ended

Dec. 31, 2014

Payables and Accruals [Abstract]

Accounts Payable and Accrued Expenses

8. Accounts Payable and Accrued Expenses:

Accounts payable and accrued expenses consist of the following (in thousands):


	December 31,
	2014		2013
Accounts payable	$	32,783	$	18,605
Accrued salaries and bonuses		231,390		189,439
Accrued payroll taxes and benefits		49,858		43,403
Accrued professional liability		19,718		19,324
Accrued contingent consideration		17,010		19,833
Other accrued expenses		29,899		18,150

	$	380,658	$	308,754

The net increase in accrued salaries and bonuses of $42.0 million, from $189.4 million at December 31, 2013 to $231.4 million at December 31, 2014, is primarily due to performance-based incentive compensation, principally to the Company’s physicians, accrued during the year ended December 31, 2014, partially offset by the payment of performance-based incentive compensation during the first quarter of 2014. A majority of the Company’s payments for performance-based incentive compensation is paid annually in the first quarter.

Accrued Professional Liability

12 Months Ended

Dec. 31, 2014

Health Care Organizations [Abstract]

Accrued Professional Liability

9. Accrued Professional Liability:

At December 31, 2014 and 2013, the Company’s total accrued professional liability of $168.4 million and $158.7 million, respectively, includes incurred but not reported loss reserves of $120.6 million and $110.3 million, respectively, and loss reserves for reported claims associated with self-insured retention amounts through the Company’s wholly owned captive insurance subsidiary of $47.8 million and $48.4 million, respectively.

The activity related to the Company’s total accrued professional liability for the years ended December 31, 2014, 2013 and 2012 is as follows (in thousands):


	Years Ended December 31,
	2014			2013			2012
Balance at beginning of year	$	158,691		$	137,036		$	122,847
Provision (adjustment) for losses related to:
Current year		39,386			41,235			35,441
Prior years		(16,125	)		(8,100	)		(8,119	)

Total provision for losses		23,261			33,135			27,322
Claim payments related to:
Current year		(293	)		(741	)		(569	)
Prior years		(13,290	)		(10,739	)		(12,564	)

Total payments		(13,583	)		(11,480	)		(13,133	)

Balance at end of year	$	168,369		$	158,691		$	137,036

The net increases in the Company’s total accrued professional liability for the years ended December 31, 2014 and 2013, are primarily attributable to increases in the current year provision for losses as a result of the increase in the number of physicians insured due to acquisitions and internal growth, offset by claim payments and adjustments to the provision for losses related to prior years resulting from favorable trends in the Company’s claims experience.

- Definition

The entire disclosure for the accrual for malpractice loss contingencies (general and professional liability) which may include the policy used for accruing the loss contingency, the nature and amount of any accrual, and any significant estimate used to determine the accrual.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 954

-SubTopic 450

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6491354&loc=d3e6052-115624

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 954

-SubTopic 450

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6491354&loc=d3e6049-115624

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14453-108349

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14394-108349

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14472-108349

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14557-108349

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14615-108349

+ Details

Long-Term Debt and Capital Lease Obligations

12 Months Ended

Dec. 31, 2014

Debt Disclosure [Abstract]

Long-Term Debt and Capital Lease Obligations

10. Long-Term Debt and Capital Lease Obligations:

On October 29, 2014, the Company entered into a new credit agreement (the “Credit Agreement”), which replaced the Company’s amended and restated credit agreement. The Credit Agreement provides for a $1.3 billion unsecured revolving credit facility and a $200 million term loan and includes a $75 million sub-facility for swingline loans and a $37.5 million sub-facility for the issuance of letters of credit. The Company may increase the credit facility to up to $1.8 billion on an unsecured basis, subject to the satisfaction of specified conditions. The new credit facility matures on October 29, 2019 and is guaranteed by substantially all of the Company’s subsidiaries and affiliated professional contractors. At the Company’s option, borrowings under the Credit Agreement (other than swingline loans) will bear interest at (i) the Alternate Base Rate (defined as the higher of (a) the prime rate, (b) the Federal Funds Rate plus 1/2 of 1.00% and (c) LIBOR for an interest period of one month plus 1.00%) plus an applicable margin rate ranging from 0.125% to 0.750% based on the Company’s consolidated leverage ratio or (ii) the LIBOR rate plus an applicable margin rate ranging from 1.125% to 1.750% based on the Company’s consolidated leverage ratio. Swingline loans will bear interest at the alternate base rate plus the applicable margin. The Credit Agreement also calls for other customary fees and charges, including an unused commitment fee ranging from 0.150% to 0.300% of the unused lending commitments, based on the Company’s consolidated leverage ratio.

The Credit Agreement contains customary covenants and restrictions, including covenants that require the Company to maintain a minimum interest coverage ratio, not to exceed a specified consolidated leverage ratio and to comply with laws. The New Credit Agreement permits us to pay dividends and make certain other distributions, subject to limitations specified therein. Failure to comply with these covenants would constitute an event of default under the Credit Agreement, notwithstanding the ability of the Company to meet its debt service obligations. The Credit Agreement also includes various customary remedies for the lenders following an event of default, including the acceleration of repayment of outstanding amounts under the Credit Agreement. At December 31, 2014, the Company believes it was in compliance, in all material respects, with the financial covenants and other restrictions applicable under the Credit Agreement.

Long-term debt consists of the following (in thousands):


	December 31,
	2014			2013
Term loan	$	200,000		$	—
Revolving line of credit		368,000			27,000

		568,000			27,000
Less: Current portion		(10,000	)		—

Long-term portion	$	558,000		$	27,000

The Company has an outstanding letter of credit associated with its professional liability insurance program which reduced the amount available under the Credit Agreement by $0.2 million at December 31, 2014. At December 31, 2014, the Company had an available balance on its Credit Agreement of $931.8 million.

Aggregate annual maturities of the Company’s term loan as of December 31, 2014 are as follows (in thousands):


2015	$	10,000
2016		10,000
2017		20,000
2018		30,000
2019 and thereafter		130,000

The Company’s capital lease obligations consist of the following (in thousands):


	December 31,
	2014			2013
Capital lease obligations	$	1,320		$	235
Less: Current portion		(465	)		(92	)

Long-term portion	$	855		$	143

The amounts due under the terms of the Company’s capital lease obligations at December 31, 2014 are as follows:


2015	$	465
2016		414
2017		332
2018		67
2019		42

Income Taxes

12 Months Ended

Dec. 31, 2014

Income Tax Disclosure [Abstract]

Income Taxes

11. Income Taxes:

The components of the income tax provision are as follows (in thousands):


	December 31,
	2014		2013		2012
Federal:
Current	$	167,745	$	134,938	$	111,940
Deferred		2,262		14,784		19,814

		170,007		149,722		131,754

State:
Current		21,109		17,037		13,980
Deferred		297		1,136		1,530

		21,406		18,173		15,510

Total	$	191,413	$	167,895	$	147,264

The Company files its tax return on a consolidated basis with its subsidiaries. The remaining affiliated professional contractors file tax returns on an individual basis.

The effective tax rate was 37.63%, 37.44% and 37.94% for the years ended December 31, 2014, 2013 and 2012, respectively.

The differences between the effective rate and the United States federal income tax statutory rate are as follows:


	December 31,
	2014			2013			2012
Tax at statutory rate		35.00	%		35.00	%		35.00	%
State income tax, net of federal benefit		2.74			2.63			2.60
Non-deductible expenses		0.33			0.27			0.36
Change in accrual estimates relating to uncertain tax positions		(0.59	)		(0.48	)		(0.15	)
Other, net		0.15			0.02			0.13

Income tax provision		37.63	%		37.44	%		37.94	%

The significant components of deferred income tax assets and liabilities are as follows (in thousands):


	December 31, 2014									December 31, 2013
	Total			Current			Non- Current			Total			Current			Non- Current
Allowance for uncollectible accounts	$	48,178		$	48,178		$	—		$	42,425		$	42,425		$	—
Reserves and accruals		62,708			26,066			36,642			52,519			18,341			34,178
Stock-based compensation		14,354			8,346			6,008			16,457			3,628			12,829
Net operating loss carryforward		10,933			1,504			9,429			6,385			3,744			2,641
Property and equipment		1,524			—			1,524			1,310			—			1,310
Other		1,461			583			878			446			446			—

Total deferred tax assets		139,158			84,677			54,481			119,542			68,584			50,958

Amortization		(214,968	)		—			(214,968	)		(162,399	)		—			(162,399	)
Accrual to cash adjustment		(38,524	)		(38,524	)		—			(37,818	)		(37,818	)		—
Other		(192	)		(192	)		—			—			—			—

Total deferred tax liabilities		(253,684	)		(38,716	)		(214,968	)		(200,217	)		(37,818	)		(162,399	)

Net deferred tax (liability) asset	$	(114,526	)	$	45,961		$	(160,487	)	$	(80,675	)	$	30,766		$	(111,441	)

The income tax benefit related to the exercise of stock options, the vesting of restricted and deferred stock and the purchase of shares under the Company’s non-qualified employee stock purchase plan in excess of amounts recorded as equity compensation expense reduces taxes currently payable and is credited to additional paid-in capital. Such amounts totaled approximately $17.5 million, $19.0 million, and $6.2 million for the years ended December 31, 2014, 2013 and 2012, respectively.

The Company has net operating loss carryforwards for federal and state tax purposes totaling approximately $29.0 million, $16.9 million, and $14.9 million at December 31, 2014, 2013 and 2012, respectively, expiring at various times in 2019 through 2034. The changes in net operating loss carryforwards in 2014 and 2013 are primarily due to timing differences related to the recognition of income for tax purposes associated with physician practice acquisitions.

As of December 31, 2014, 2013 and 2012, the Company’s liability for uncertain tax positions, excluding accrued interest and penalties, was $17.2 million, $14.9 million and $13.1 million, respectively. The Company had approximately $16.1 million of uncertain tax positions that, if recognized, would favorably impact its effective tax rate at December 31, 2014.

The following table summarizes the activity related to the Company’s liability for uncertain tax positions for the years ended December 31, 2014, 2013 and 2012 (in thousands):


	Years Ended December 31,
	2014			2013			2012
Balance at beginning of year	$	14,902		$	13,072		$	16,165
Increases related to prior year tax positions		40			338			102
Decreases related to prior year tax positions		—			(38	)		—
Increases related to current year tax positions		3,750			2,955			2,478
Decreases related to current year tax positions		—			—			(3,671	)
Decreases related to lapse of statutes of limitations		(1,527	)		(1,425	)		(2,002	)

Balance at end of year	$	17,165		$	14,902		$	13,072

During the years ended December 31, 2014 and 2013, the Company increased its liability for uncertain tax positions by a total of $2.3 million and $1.8 million, respectively, primarily related to additional taxes on current year positions, partially offset by decreases due to the expiration of statutes of limitation.

The Company includes interest and penalties related to income tax liabilities in income tax expense. The Company recognized a net increase of $0.3 million related to interest and penalties during the year ended December 31, 2014. The Company recognized a net decrease of $0.6 million and a net increase of $0.3 million, respectively, of interest and penalties related to income tax liabilities during the years ended December 31, 2013 and 2012. At December 31, 2014 and 2013, the Company’s accrued liability for interest and penalties related to income tax liabilities totaled $8.7 million and $8.4 million, respectively.

At December 31, 2014 and 2013, the Company’s total liability for uncertain tax positions of $25.9 million and $23.3 million, respectively, is included in other liabilities as presented in the Company’s Consolidated Balance Sheet.

The Company anticipates that its liability for uncertain tax positions will be increased by approximately $4.9 million for additional taxes and decreased by approximately $1.7 million related to the expiration of certain statutes of limitation over the next 12 months.

The Company is currently subject to U.S. Federal and various state income tax examinations for the tax years 2004 through 2013.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References+ Details

Common and Common Equivalent Shares

12 Months Ended

Dec. 31, 2014

Earnings Per Share [Abstract]

Common and Common Equivalent Shares

12. Common and Common Equivalent Shares:

The calculation of shares used in the basic and diluted net income per share calculation for the years ended December 31, 2014, 2013 and 2012 is as follows (in thousands):


	Years Ended December 31,
	2014		2013		2012
Weighted average number of common shares outstanding		98,588		99,112		97,386
Weighted average number of dilutive common share equivalents		1,299		1,857		1,996

Weighted average number of common and common equivalent shares outstanding		99,887		100,969		99,382

Antidilutive securities not included in the diluted net income per common share calculation		1		35		58

- Definition

The entire disclosure for earnings per share.

+ References+ Details

Stock Incentive Plans and Stock Purchase Plan

12 Months Ended

Dec. 31, 2014

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Stock Incentive Plans and Stock Purchase Plan

13. Stock Incentive Plans and Stock Purchase Plan:

The Company’s Amended and Restated 2008 Incentive Compensation Plan, as amended (the “Amended and Restated 2008 Incentive Plan”) provides for grants of stock options, stock appreciation rights, restricted stock, deferred stock, and other stock-related awards and performance awards that may be settled in cash, stock or other property.

Under the Amended and Restated 2008 Incentive Plan, options to purchase shares of common stock may be granted at a price not less than the fair market value of the shares on the date of grant. The options must be exercised within 10 years from the date of grant and generally become exercisable on a pro rata basis over a three-year period from the date of grant. The Company issues new shares of its common stock upon exercise of its stock options. Restricted stock awards generally vest over periods of three years upon the fulfillment of specified service-based conditions and in certain instances performance-based conditions. Deferred stock awards generally vest upon the satisfaction of specified performance-based conditions or service-based conditions. The Company recognizes compensation expense related to its restricted stock and deferred stock awards ratably over the corresponding vesting periods. At December 31, 2014, the Company had approximately 6.3 million shares available for future grants and awards under its Amended and Restated 2008 Incentive Plan.

Under the Company’s 1996 Non-Qualified Employee Stock Purchase Plan, as amended (the “Stock Purchase Plan”), employees are permitted to purchase the Company’s common stock at 85% of market value on January 1st, April 1st, July 1st and October 1st of each year. In accordance with the provisions of the accounting guidance for stock-based compensation, the Company recognizes stock-based compensation expense for the 15% discount received by participating employees. During the year ended December 31, 2014, approximately 260,000 shares were issued under the Stock Purchase Plan. At December 31, 2014, the Company had approximately 335,000 shares reserved for issuance under the Stock Purchase Plan.

The Company recognized approximately $31.7 million, $31.3 million and $28.4 million of stock-based compensation expense related to its stock incentive plans and the Stock Purchase Plan during the years ended December 31, 2014, 2013 and 2012, respectively.

The activity related to the Company’s restricted and deferred stock awards and the corresponding weighted average grant-date fair values for the year ended December 31, 2014 are as follows:


	Number of Shares			Weighted Average Fair Value
Non-vested shares at January 1, 2014		1,519,976		$	37.78
Awarded		529,431		$	57.73
Forfeited		(33,569	)	$	42.19
Vested		(744,794	)	$	37.90

Non-vested shares at December 31, 2014		1,271,044		$	46.80

The aggregate fair value of the restricted and deferred stock that vested during the years ended December 31, 2014, 2013 and 2012 was approximately $28.2 million, $33.3 million and $23.0 million, respectively.

The weighted average grant-date fair value of restricted and deferred stock awards that were granted during the years ended December 31, 2014, 2013 and 2012 was $57.73, $46.48 and $30.06, respectively.

At December 31, 2014, the total stock-based compensation cost related to non-vested restricted and deferred stock remaining to be recognized as compensation expense over a weighted-average period of approximately 1.4 years was $26.1 million.

The Company did not grant any stock options during 2014 or 2013, and all stock-based compensation cost related to stock options has been recognized. The activity and certain other information related to the Company’s outstanding stock option awards for the year ended December 31, 2014 are as follows:


	Number of Stock Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value (in millions)
Outstanding at January 1, 2014		1,966,170		$	26.74
Exercised		(1,151,576	)	$	26.16			$	38.8
Forfeited		(500	)	$	27.72				—

Outstanding and exercisable at December 31, 2014		814,094		$	27.57		3.6	$	31.4

The aggregate intrinsic value of stock options exercised during the years ended December 31, 2014, 2013 and 2012 was $38.8 million, $35.4 million and $18.1 million, respectively.

The net excess tax benefit recognized in additional paid-in capital related primarily to stock options, restricted stock and deferred stock for the years ended December 31, 2014, 2013 and 2012 was approximately $17.5 million, $19.0 million and $6.2 million, respectively. The cash proceeds received from the exercise of stock options for the years ended December 31, 2014, 2013 and 2012 were approximately $30.1 million, $18.9 million and $20.8 million, respectively.

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References+ Details

Common Stock Repurchase Programs	12 Months Ended
Common Stock Repurchase Programs	Dec. 31, 2014
Text Block [Abstract]
Common Stock Repurchase Programs	14. Common Stock Repurchase Programs: In July 2013, the Company’s Board of Directors authorized the repurchase of shares of the Company’s common stock up to an amount sufficient to offset the dilutive impact from the issuance of shares under our equity compensation programs. The share repurchase program allows the Company to make open market purchases from time-to-time based on general economic and market conditions and trading restrictions. The repurchase program also allows for the repurchase of shares of the Company’s common stock to offset the dilutive impact from the issuance of shares, if any, related to the Company’s acquisition program. In October 2014, the Company announced that its Board of Directors had authorized the repurchase of up to $600.0 million of shares of the Company’s common stock in addition to its existing share repurchase program. During the year ended December 31, 2014, the Company repurchased approximately 7.1 million shares of its common stock for approximately $488.4 million, including shares withheld to satisfy minimum statutory tax withholding obligations with a fair value of $1.1 million in connection with the vesting of deferred stock during the period and the aggregate value of common stock held back pending final settlement of an accelerated share repurchase program discussed below. On December 15, 2014, the Company entered into uncollared accelerated share repurchase (“ASR”) agreement with an investment bank. Under the ASR agreement, the Company agreed to purchase $200.0 million of its common stock in total. On December 17, 2014, the Company paid a total of $200.0 million to an investment bank, which in turn delivered to the Company approximately 2.5 million shares of the Company’s common stock in total based on the market price of a share of Company common stock on December 12, 2014. The payment was recorded as a reduction to the respective components of shareholders’ equity. The final number of shares of common stock that the Company may receive, or may be required to remit, upon settlement under the ASR agreement will be based upon the average daily volume weighted-average price of the Company’s common stock during the term of the ASR agreement, less a negotiated discount. Final settlement of the ASR agreement is expected to occur within seven months of commencement of the program, and may occur earlier at the option of the investment bank. The terms of the ASR agreement are subject to adjustment if the Company were to enter into or announce certain types of transactions that may affect the Company’s common stock. If the Company is obligated to make an adjustment payment to the investment bank under the ASR agreement, the Company may elect to satisfy such obligation in cash or in shares of the Company’s common stock. The ASR agreement was funded by borrowings under the Company’s Credit Agreement discussed in Note 10. The Company intends to utilize various methods to effect any additional share repurchases, including, among others, open market purchases and accelerated share repurchase programs. The amount and timing of repurchases will depend upon several factors, including general economic and market conditions and trading restrictions.

Retirement Plans

12 Months Ended

Dec. 31, 2014

Compensation and Retirement Disclosure [Abstract]

Retirement Plans

15.

Retirement Plans:

The Company maintains three qualified contributory savings plans as allowed under Section 401(k) of the Internal Revenue Code and Section 1165(e) of the Puerto Rico Income Tax Act of 1954 (the “401(k) Plans”). The 401(k) Plans permit participant contributions and allow elective and, in certain situations, non-elective Company contributions based on each participant’s contribution or a specified percentage of eligible wages. Participants may defer a percentage of their annual compensation subject to the limits defined in the 401(k) Plans. The Company recorded expense of $34.3 million, $29.8 million and $24.8 million for the years ended December 31, 2014, 2013 and 2012, respectively, primarily related to the 401(k) Plans.

- Definition

The entire disclosure for pension and other postretirement benefits.

+ References+ Details

Commitments and Contingencies

12 Months Ended

Dec. 31, 2014

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

16. Commitments and Contingencies:

The Company expects that audits, inquiries and investigations from government authorities and agencies will occur in the ordinary course of business. Such audits, inquiries and investigations and their ultimate resolutions, individually or in the aggregate, could have a material adverse effect on the Company’s business, financial condition, results of operations, cash flows and the trading price of its common stock. The Company has not included an accrual for these matters as of December 31, 2014 in its Consolidated Financial Statements, as the variables affecting any potential eventual liability depend on the currently unknown facts and circumstances that arise out of, and are specific to, any particular future audit, inquiry and investigation and cannot be reasonably estimated at this time.

In the ordinary course of business, the Company becomes involved in pending and threatened legal actions and proceedings, most of which involve claims of medical malpractice related to medical services provided by the Company’s affiliated physicians. The Company’s contracts with hospitals generally require the Company to indemnify them and their affiliates for losses resulting from the negligence of the Company’s affiliated physicians. The Company may also become subject to other lawsuits which could involve large claims and significant costs. The Company believes, based upon a review of pending actions and proceedings, that the outcome of such legal actions and proceedings will not have a material adverse effect on its business, financial condition or results of operations. The outcome of such actions and proceedings, however, cannot be predicted with certainty and an unfavorable resolution of one or more of them could have a material adverse effect on the Company’s business, financial condition, results of operations, cash flows and the trading price of its common stock.

Although the Company currently maintains liability insurance coverage intended to cover professional liability and certain other claims, the Company cannot assure that its insurance coverage will be adequate to cover liabilities arising out of claims asserted against it in the future where the outcomes of such claims are unfavorable. With respect to professional liability risk, the Company generally self-insures a portion of this risk through its wholly owned captive insurance subsidiary. Liabilities in excess of the Company’s insurance coverage, including coverage for professional liability and certain other claims, could have a material adverse effect on the Company’s business, financial condition and results of operations.

The Company leases space for its regional, medical and business offices, storage space and temporary housing of medical staff. The Company also leases an aircraft. Rent expense for the years ended December 31, 2014, 2013 and 2012 was approximately $27.8 million, $26.4 million, and $23.9 million, respectively.

Future minimum lease payments under non-cancelable operating leases as of December 31, 2014 are as follows (in thousands):


2015	$	27,272
2016		21,579
2017		16,894
2018		12,347
2019		7,600
Thereafter		10,928

	$	96,620

- Definition

The entire disclosure for commitments and contingencies.

+ References+ Details

Selected Quarterly Financial Information

12 Months Ended

Dec. 31, 2014

Quarterly Financial Information Disclosure [Abstract]

Selected Quarterly Financial Information

17. Selected Quarterly Financial Information (Unaudited):

The following tables set forth a summary of the Company’s selected quarterly financial information for each of the four quarters ended December 31, 2014 and 2013 (in thousands, except for per share data):


	2014 Quarters
	First			Second			Third			Fourth
Net revenue	$	566,338		$	595,544		$	626,506		$	650,525

Operating expenses:
Practice salaries and benefits		372,040			372,216			394,794			404,345
Practice supplies and other operating expenses		21,417			22,466			21,570			23,549
General and administrative expenses		58,414			60,829			60,643			67,641
Depreciation and amortization		10,370			10,361			11,356			13,903

Total operating expenses		462,241			465,872			488,363			509,438

Income from operations		104,097			129,672			138,143			141,087
Investment income		1,635			335			563			195
Interest expense		(1,371	)		(2,188	)		(2,019	)		(3,313	)
Equity in earnings of unconsolidated affiliate		—			150			725			905

Total non-operating expenses		264			(1,703	)		(731	)		(2,213	)
Income before income taxes		104,361			127,969			137,412			138,874
Income tax provision		40,701			48,944			51,174			50,594

Net income		63,660			79,025			86,238			88,280
Net (income) loss attributable to noncontrolling interests		—			(9	)		(31	)		118

Net income attributable to MEDNAX, Inc.	$	63,660		$	79,016		$	86,207		$	88,398

Per common and common equivalent share data (1):
Net income attributable to MEDNAX, Inc.:
Basic	$	0.64		$	0.80		$	0.87		$	0.90

Diluted	$	0.63		$	0.79		$	0.86		$	0.89

Weighted average common shares:
Basic		99,076			98,411			99,088			98,066

Diluted		100,696			99,866			100,145			99,129

(1)	Basic and diluted per share amounts are computed for each of the periods presented. Accordingly, the sum of the quarterly per share amounts may not agree with the full year amount.


	2013 Quarters
	First			Second			Third			Fourth
Net revenue	$	502,715		$	529,180		$	554,730		$	567,387

Operating expenses:
Practice salaries and benefits		329,201			331,922			346,879			353,316
Practice supplies and other operating expenses		19,500			19,416			19,445			24,027
General and administrative expenses		53,318			54,601			54,654			55,636
Depreciation and amortization		9,144			9,870			10,461			10,491

Total operating expenses		411,163			415,809			431,439			443,470

Income from operations		91,552			113,371			123,291			123,917
Investment income		402			396			372			526
Interest expense		(1,189	)		(1,673	)		(1,507	)		(1,046	)

Income before income taxes		90,765			112,094			122,156			123,397
Income tax provision		35,398			42,876			45,198			44,423

Net income	$	55,367		$	69,218		$	76,958		$	78,974

Per common and common equivalent share data (1):
Net income:
Basic	$	0.56		$	0.70		$	0.77		$	0.79

Diluted	$	0.55		$	0.68		$	0.76		$	0.78

Weighted average shares:
Basic		98,618			99,116			99,506			99,469

Diluted		100,784			101,098			101,178			101,080

(1)	Basic and diluted per share amounts are computed for each of the periods presented. Accordingly, the sum of the quarterly per share amounts may not agree with the full year amount.

- Definition

The entire disclosure for the quarterly financial data in the annual financial statements. The disclosure may include a tabular presentation of financial information for each fiscal quarter for the current and previous year, including revenues, gross profit, income or loss before extraordinary items and earnings per share data. It also includes an indication if the information in the note is unaudited, comments on the aggregate effect of year-end adjustments, and an explanation of matters or transactions that affect comparability or are pertinent to an understanding of the information furnished.

+ References+ Details

Schedule II: Valuation and Qualifying Accounts

12 Months Ended

Dec. 31, 2014

Valuation and Qualifying Accounts [Abstract]

Schedule II: Valuation and Qualifying Accounts

Schedule II: Valuation and Qualifying Accounts


	Years Ended December 31,
	2014			2013			2012
Allowance for contractual adjustments and uncollectibles:
Balance at beginning of year	$	712,285		$	624,896		$	576,030
Amount charged against operating revenue		5,403,437			4,695,232			3,994,924
Accounts receivable contractual adjustments and write-offs (net of recoveries)		(5,266,955	)		(4,607,843	)		(3,946,058	)

Balance at end of year	$	848,767		$	712,285		$	624,896

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2014

Accounting Policies [Abstract]

Principles of Presentation

Principles of Presentation

All share and per share data set forth herein give effect to the two-for-one split of the Company’s common stock that became effective on December 19, 2013.

New Accounting Pronouncements

New Accounting Pronouncements

Accounting Estimates and Assumptions

Accounting Estimates and Assumptions

Segment Reporting

Segment Reporting

The following table summarizes the Company’s net revenue by specialties and subspecialties (in percentages):


	Years Ended December 31,
	2014			2013			2012
Neonatal and other pediatric subspecialties		50	%		52	%		56	%
Anesthesia		36	%		32	%		27	%
Maternal-fetal		9	%		11	%		12	%
Pediatric cardiology		4	%		5	%		5	%
Other services		1	%		—			—

		100	%		100	%		100	%

Revenue Recognition

Revenue Recognition

Cash Equivalents

Cash Equivalents

Certain cash equivalents carried by the Company are subject to the fair value provisions of the accounting guidance for fair value measurements. See “Fair Value Measurements” below.

Investments

Investments

Property and Equipment

Property and Equipment

Business Acquisitions

Business Acquisitions

Goodwill and Other Intangible Assets

Goodwill and Other Intangible Assets

Long-Lived Assets

Long-Lived Assets

Common Stock Repurchases

Common Stock Repurchases

Professional Liability Coverage

Professional Liability Coverage

Income Taxes

Income Taxes

Stock Incentive Plans

Stock Incentive Plans

Net Income Per Common Share

Net Income Per Common Share

Fair Value Measurements

Fair Value Measurements

The carrying amounts of cash equivalents, short-term investments, accounts receivable and accounts payable and accrued expenses approximate fair value due to the short maturities of the respective instruments. The carrying values of long-term investments, line of credit, long term-debt and capital lease obligations approximate fair value. If the Company’s line of credit and long-term debt were measured at fair value, they would be categorized as Level 2 in the fair value hierarchy.

Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2014

Accounting Policies [Abstract]

Schedule of Net Revenue by Specialties and Subspecialties

The following table summarizes the Company’s net revenue by specialties and subspecialties (in percentages):


	Years Ended December 31,
	2014			2013			2012
Neonatal and other pediatric subspecialties		50	%		52	%		56	%
Anesthesia		36	%		32	%		27	%
Maternal-fetal		9	%		11	%		12	%
Pediatric cardiology		4	%		5	%		5	%
Other services		1	%		—			—

		100	%		100	%		100	%

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References+ Details

Investments (Tables)

12 Months Ended

Dec. 31, 2014

Investments, Debt and Equity Securities [Abstract]

Schedule of Investments

Investments held are summarized as follows (in thousands):


	December 31, 2014				December 31, 2013
	Short-Term		Long-Term		Short-Term		Long-Term
Municipal debt securities	$	5,539	$	35,827	$	5,492	$	34,495
Federal home loan securities		—		27,030		—		22,520
Certificates of deposit		496		1,225		965		496

	$	6,035	$	64,082	$	6,457	$	57,511

Schedule of Contractual Maturities of Long-Term Investments

Contractual maturities of long-term investments are summarized as follows (in thousands):


	December 31,
	2014		2013
Due after one year through five years	$	54,959	$	41,655
Due after five years through seven years		9,123		15,856

	$	64,082	$	57,511

- Definition

Tabular disclosure of all investments in certain debt and equity securities for which the entity has the positive intent and ability to hold until maturity.

+ References+ Details

Accounts Receivable and Net Revenue (Tables)

12 Months Ended

Dec. 31, 2014

Text Block [Abstract]

Schedule of Accounts Receivable, Net

Accounts receivable, net consists of the following (in thousands):


	December 31,
	2014			2013
Gross accounts receivable	$	1,200,958		$	997,682
Allowance for contractual adjustments and uncollectibles		(848,767	)		(712,285)

	$	352,191		$	285,397

Schedule of Net Revenue

Net revenue consists of the following (in thousands):


	Years Ended December 31,
	2014			2013			2012
Gross revenue	$	7,662,556		$	6,702,484		$	5,691,790
Contractual adjustments and uncollectibles		(5,403,437	)		(4,695,232	)		(3,994,924	)
Hospital contract administrative fees		179,794			146,760			119,746

	$	2,438,913		$	2,154,012		$	1,816,612

Property and Equipment (Tables)

12 Months Ended

Dec. 31, 2014

Property, Plant and Equipment [Abstract]

Schedule of Property and Equipment

Property and equipment consists of the following (in thousands):


	December 31,
	2014			2013
Building	$	22,981		$	22,981
Land		6,683			6,683
Equipment and other		133,279			117,246

		162,943			146,910
Accumulated depreciation		(96,895	)		(86,999	)

	$	66,048		$	59,911

Business Acquisitions (Tables)

12 Months Ended

Dec. 31, 2014

Business Combinations [Abstract]

Summary of Company's Purchase Allocation Price

The Company’s allocation of purchase price is as follows:


Current assets	$	11.8
Property and equipment		3.8
Goodwill		389.6
Other intangible assets		124.8
Current liabilities		(14.4	)
Deferred income tax liabilities—long-term		(26.3	)
Other long-term liabilities		(0.7	)

	$	488.6

Schedule of Pro Forma Information Combines Consolidated Results of Company and Business Acquisitions

The following unaudited pro forma information combines the consolidated results of operations of the Company on a GAAP basis and the acquisitions completed during 2014 and 2013, including adjustments for pro forma amortization and interest expense, as if the transactions had occurred on January 1, 2013 and January 1, 2012, respectively (in thousands, except per share data):


	Years Ended December 31,
	2014		2013
Net revenue	$	2,590,384	$	2,494,968
Net income		326,216		301,076
Net income per common share (1):
Basic	$	3.31	$	3.04
Diluted	$	3.27	$	2.98
Weighted average common shares (1):
Basic		98,588		99,112
Diluted		99,887		100,969

(1)	The comparison of net income per common share is affected by the changes in the number of weighted average shares outstanding in each period.

Goodwill and Other Assets (Tables)

12 Months Ended

Dec. 31, 2014

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Other Assets

Other assets consist of the following (in thousands):


	December 31,
	2014		2013
Other intangible assets, net	$	198,136	$	103,639
Other assets		37,289		25,799

	$	235,425	$	129,438

Amortization Expenses for Existing Other Intangible Assets for the Next Five Years

Amortization expense for existing other intangible assets for the next five years is expected to be as follows (in thousands):


2015	$	36,874
2016		30,985
2017		24,919
2018		20,190
2019		16,059

Accounts Payable and Accrued Expenses (Tables)

12 Months Ended

Dec. 31, 2014

Payables and Accruals [Abstract]

Schedule of Accounts Payable and Accrued Expenses

Accounts payable and accrued expenses consist of the following (in thousands):


	December 31,
	2014		2013
Accounts payable	$	32,783	$	18,605
Accrued salaries and bonuses		231,390		189,439
Accrued payroll taxes and benefits		49,858		43,403
Accrued professional liability		19,718		19,324
Accrued contingent consideration		17,010		19,833
Other accrued expenses		29,899		18,150

	$	380,658	$	308,754

Accrued Professional Liability (Tables)

12 Months Ended

Dec. 31, 2014

Health Care Organizations [Abstract]

Schedule of Accrued Professional Liability

The activity related to the Company’s total accrued professional liability for the years ended December 31, 2014, 2013 and 2012 is as follows (in thousands):


	Years Ended December 31,
	2014			2013			2012
Balance at beginning of year	$	158,691		$	137,036		$	122,847

Provision (adjustment) for losses related to:
Current year		39,386			41,235			35,441
Prior years		(16,125	)		(8,100	)		(8,119	)

Total provision for losses		23,261			33,135			27,322

Claim payments related to:
Current year		(293	)		(741	)		(569	)
Prior years		(13,290	)		(10,739	)		(12,564	)

Total payments		(13,583	)		(11,480	)		(13,133	)

Balance at end of year	$	168,369		$	158,691		$	137,036

Long-Term Debt and Capital Lease Obligations (Tables)

12 Months Ended

Dec. 31, 2014

Debt Disclosure [Abstract]

Schedule of Long-Term Debt

Long-term debt consists of the following (in thousands):


	December 31,
	2014			2013
Term loan	$	200,000		$	—
Revolving line of credit		368,000			27,000

		568,000			27,000
Less: Current portion		(10,000	)		—

Long-term portion	$	558,000		$	27,000

Schedule of Aggregate Annual Maturities of Term Loan

Aggregate annual maturities of the Company’s term loan as of December 31, 2014 are as follows (in thousands):


2015	$	10,000
2016		10,000
2017		20,000
2018		30,000
2019 and thereafter		130,000

Schedule of Capital Lease Obligations

The Company’s capital lease obligations consist of the following (in thousands):


	December 31,
	2014			2013
Capital lease obligations	$	1,320		$	235
Less: Current portion		(465	)		(92	)

Long-term portion	$	855		$	143

Schedule of Amounts Due Under Terms of Capital Lease Obligations

The amounts due under the terms of the Company’s capital lease obligations at December 31, 2014 are as follows:


2015	$	465
2016		414
2017		332
2018		67
2019		42

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2014

Income Tax Disclosure [Abstract]

Summary of Components of Income Tax Provision

The components of the income tax provision are as follows (in thousands):


	December 31,
	2014		2013		2012
Federal:
Current	$	167,745	$	134,938	$	111,940
Deferred		2,262		14,784		19,814

		170,007		149,722		131,754

State:
Current		21,109		17,037		13,980
Deferred		297		1,136		1,530

		21,406		18,173		15,510

Total	$	191,413	$	167,895	$	147,264

Schedule of Differences Between Effective Rate and United States Federal Income Tax Statutory Rate

The differences between the effective rate and the United States federal income tax statutory rate are as follows:


	December 31,
	2014			2013			2012
Tax at statutory rate		35.00	%		35.00	%		35.00	%
State income tax, net of federal benefit		2.74			2.63			2.60
Non-deductible expenses		0.33			0.27			0.36
Change in accrual estimates relating to uncertain tax positions		(0.59	)		(0.48	)		(0.15	)
Other, net		0.15			0.02			0.13

Income tax provision		37.63	%		37.44	%		37.94	%

Significant Components of Deferred Income Tax Assets And Liabilities

The significant components of deferred income tax assets and liabilities are as follows (in thousands):


	December 31, 2014									December 31, 2013
	Total			Current			Non- Current			Total			Current			Non- Current
Allowance for uncollectible accounts	$	48,178		$	48,178		$	—		$	42,425		$	42,425		$	—
Reserves and accruals		62,708			26,066			36,642			52,519			18,341			34,178
Stock-based compensation		14,354			8,346			6,008			16,457			3,628			12,829
Net operating loss carryforward		10,933			1,504			9,429			6,385			3,744			2,641
Property and equipment		1,524			—			1,524			1,310			—			1,310
Other		1,461			583			878			446			446			—

Total deferred tax assets		139,158			84,677			54,481			119,542			68,584			50,958

Amortization		(214,968	)		—			(214,968	)		(162,399	)		—			(162,399	)
Accrual to cash adjustment		(38,524	)		(38,524	)		—			(37,818	)		(37,818	)		—
Other		(192	)		(192	)		—			—			—			—

Total deferred tax liabilities		(253,684	)		(38,716	)		(214,968	)		(200,217	)		(37,818	)		(162,399	)

Net deferred tax (liability) asset	$	(114,526	)	$	45,961		$	(160,487	)	$	(80,675	)	$	30,766		$	(111,441	)

Schedule of Activity Related to Gross Unrecognized Tax Benefits

The following table summarizes the activity related to the Company’s liability for uncertain tax positions for the years ended December 31, 2014, 2013 and 2012 (in thousands):


	Years Ended December 31,
	2014			2013			2012
Balance at beginning of year	$	14,902		$	13,072		$	16,165
Increases related to prior year tax positions		40			338			102
Decreases related to prior year tax positions		—			(38	)		—
Increases related to current year tax positions		3,750			2,955			2,478
Decreases related to current year tax positions		—			—			(3,671	)
Decreases related to lapse of statutes of limitations		(1,527	)		(1,425	)		(2,002	)

Balance at end of year	$	17,165		$	14,902		$	13,072

- Definition

Tabular disclosure of tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities (i.e., uncertain tax positions) and other types of income tax contingencies, including: (1) the policy on classification of interest and penalties; (2) a tabular reconciliation of the total amounts of unrecognized tax benefits at the beginning and end of the period; the total amount(s) of: (3) unrecognized tax benefits that, if recognized, would affect the effective tax rate, and (4) interest and penalties recognized in each of the income statement and balance sheet; (5) for positions for which it is reasonably possible that the total amounts unrecognized will significantly change within 12 months of the reporting date the: (i) nature of the uncertainty, (ii) nature of the event that could occur that would cause the change, and (iii) an estimate of the range of the reasonably possible change or a statement that an estimate of the range cannot be made; and (6) a description of tax years that remain subject to examination by major tax jurisdictions.

+ References+ Details

Common and Common Equivalent Shares (Tables)

12 Months Ended

Dec. 31, 2014

Earnings Per Share [Abstract]

Schedule of Calculation of Shares Used in Basic and Diluted Net Income Per Share

The calculation of shares used in the basic and diluted net income per share calculation for the years ended December 31, 2014, 2013 and 2012 is as follows (in thousands):


	Years Ended December 31,
	2014		2013		2012
Weighted average number of common shares outstanding		98,588		99,112		97,386
Weighted average number of dilutive common share equivalents		1,299		1,857		1,996

Weighted average number of common and common equivalent shares outstanding		99,887		100,969		99,382

Antidilutive securities not included in the diluted net income per common share calculation		1		35		58

Stock Incentive Plans and Stock Purchase Plan (Tables)

12 Months Ended

Dec. 31, 2014

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of Weighted Average Grant-Date Fair Values

The activity related to the Company’s restricted and deferred stock awards and the corresponding weighted average grant-date fair values for the year ended December 31, 2014 are as follows:


	Number of Shares			Weighted Average Fair Value
Non-vested shares at January 1, 2014		1,519,976		$	37.78
Awarded		529,431		$	57.73
Forfeited		(33,569	)	$	42.19
Vested		(744,794	)	$	37.90

Non-vested shares at December 31, 2014		1,271,044		$	46.80

Schedule of Activity and Certain Other Information Related to Stock Option Awards

The activity and certain other information related to the Company’s outstanding stock option awards for the year ended December 31, 2014 are as follows:


	Number of Stock Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value (in millions)
Outstanding at January 1, 2014		1,966,170		$	26.74
Exercised		(1,151,576	)	$	26.16			$	38.8
Forfeited		(500	)	$	27.72				—

Outstanding and exercisable at December 31, 2014		814,094		$	27.57		3.6	$	31.4

Commitments and Contingencies (Tables)

12 Months Ended

Dec. 31, 2014

Commitments and Contingencies Disclosure [Abstract]

Schedule of Future Minimum Lease Payments under Non-Cancelable Operating Leases

Future minimum lease payments under non-cancelable operating leases as of December 31, 2014 are as follows (in thousands):


2015	$	27,272
2016		21,579
2017		16,894
2018		12,347
2019		7,600
Thereafter		10,928

	$	96,620

Selected Quarterly Financial Information (Tables)

12 Months Ended

Dec. 31, 2014

Quarterly Financial Information Disclosure [Abstract]

Summary of Company's Selected Quarterly Financial Information


	2014 Quarters
	First			Second			Third			Fourth
Net revenue	$	566,338		$	595,544		$	626,506		$	650,525

Operating expenses:
Practice salaries and benefits		372,040			372,216			394,794			404,345
Practice supplies and other operating expenses		21,417			22,466			21,570			23,549
General and administrative expenses		58,414			60,829			60,643			67,641
Depreciation and amortization		10,370			10,361			11,356			13,903

Total operating expenses		462,241			465,872			488,363			509,438

Income from operations		104,097			129,672			138,143			141,087
Investment income		1,635			335			563			195
Interest expense		(1,371	)		(2,188	)		(2,019	)		(3,313	)
Equity in earnings of unconsolidated affiliate		—			150			725			905

Total non-operating expenses		264			(1,703	)		(731	)		(2,213	)
Income before income taxes		104,361			127,969			137,412			138,874
Income tax provision		40,701			48,944			51,174			50,594

Net income		63,660			79,025			86,238			88,280
Net (income) loss attributable to noncontrolling interests		—			(9	)		(31	)		118

Net income attributable to MEDNAX, Inc.	$	63,660		$	79,016		$	86,207		$	88,398

Per common and common equivalent share data (1):
Net income attributable to MEDNAX, Inc.:
Basic	$	0.64		$	0.80		$	0.87		$	0.90

Diluted	$	0.63		$	0.79		$	0.86		$	0.89

Weighted average common shares:
Basic		99,076			98,411			99,088			98,066

Diluted		100,696			99,866			100,145			99,129

(1)	Basic and diluted per share amounts are computed for each of the periods presented. Accordingly, the sum of the quarterly per share amounts may not agree with the full year amount.


	2013 Quarters
	First			Second			Third			Fourth
Net revenue	$	502,715		$	529,180		$	554,730		$	567,387

Operating expenses:
Practice salaries and benefits		329,201			331,922			346,879			353,316
Practice supplies and other operating expenses		19,500			19,416			19,445			24,027
General and administrative expenses		53,318			54,601			54,654			55,636
Depreciation and amortization		9,144			9,870			10,461			10,491

Total operating expenses		411,163			415,809			431,439			443,470

Income from operations		91,552			113,371			123,291			123,917
Investment income		402			396			372			526
Interest expense		(1,189	)		(1,673	)		(1,507	)		(1,046	)

Income before income taxes		90,765			112,094			122,156			123,397
Income tax provision		35,398			42,876			45,198			44,423

Net income	$	55,367		$	69,218		$	76,958		$	78,974

Per common and common equivalent share data (1):
Net income:
Basic	$	0.56		$	0.70		$	0.77		$	0.79

Diluted	$	0.55		$	0.68		$	0.76		$	0.78

Weighted average shares:
Basic		98,618			99,116			99,506			99,469

Diluted		100,784			101,098			101,178			101,080

(1)	Basic and diluted per share amounts are computed for each of the periods presented. Accordingly, the sum of the quarterly per share amounts may not agree with the full year amount.

Summary of Significant Accounting Policies - Additional Information (Detail) (USD $) In Millions, unless otherwise specified	0 Months Ended	12 Months Ended			12 Months Ended
	Dec. 19, 2013	Dec. 31, 2014	Jun. 01, 2014	Dec. 31, 2013	Dec. 31, 2014 Government Contracts Concentration Risk [Member] Accounts Receivable [Member]	Dec. 31, 2013 Government Contracts Concentration Risk [Member] Accounts Receivable [Member]	Dec. 31, 2014 Restatement Adjustment [Member]	Dec. 31, 2014 Buildings [Member]	Dec. 31, 2014 Maximum [Member]	Dec. 31, 2014 Maximum [Member] Medical Equipment [Member]	Dec. 31, 2014 Maximum [Member] Computer Equipment [Member]	Dec. 31, 2014 Maximum [Member] Software and Software Development Costs [Member]	Dec. 31, 2014 Maximum [Member] Furniture [Member]	Dec. 31, 2014 Minimum [Member]	Dec. 31, 2014 Minimum [Member] Medical Equipment [Member]	Dec. 31, 2014 Minimum [Member] Computer Equipment [Member]	Dec. 31, 2014 Minimum [Member] Software and Software Development Costs [Member]	Dec. 31, 2014 Minimum [Member] Furniture [Member]
Summary Of Significant Accounting Policies [Line Items]
Equity method ownership percentage in joint venture		37.50%	37.50%
Direct ownership percentage in joint venture			75.00%
Deferred income taxes, reclassification adjustment from current to long-term							$ 40.7
Stock split ratio	2
Percentage of net accounts receivable					20.00%	20.00%
Long-term investments maturity period, in years									7 years					1 year
Short-Term investments maturity period, in years									1 year
Property and equipment estimated useful lives, years								20 years		10 years	10 years	10 years	10 years		3 years	3 years	3 years	3 years
Additional amounts to be paid in cash or common stock based on achievement of performance measures within period, maximum years		5 years
Intangible assets finite lives		8 years 8 months 12 days							20 years					1 year
Money market funds carrying amount		5.1		5.3
Carrying amount of cash surrender value of life insurance		16.0		17.1
Contingent consideration liabilities related to acquisitions		$ 35.3		$ 43.0

Summary of Significant Accounting Policies - Schedule of Net Revenue by Specialties and Subspecialties (Detail) (Product Concentration Risk [Member], Sales Revenue, Services, Net [Member])	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Segment Reporting Information [Line Items]
Net revenue in percentage	100.00%	100.00%	100.00%
Neonatal and Other Pediatric Subspecialties [Member]
Segment Reporting Information [Line Items]
Net revenue in percentage	50.00%	52.00%	56.00%
Anesthesia [Member]
Segment Reporting Information [Line Items]
Net revenue in percentage	36.00%	32.00%	27.00%
Maternal-Fetal [Member]
Segment Reporting Information [Line Items]
Net revenue in percentage	9.00%	11.00%	12.00%
Pediatric Cardiology [Member]
Segment Reporting Information [Line Items]
Net revenue in percentage	4.00%	5.00%	5.00%
Other Services [Member]
Segment Reporting Information [Line Items]
Net revenue in percentage	1.00%

Investments - Schedule of Investments (Detail) (USD $) In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Schedule of Held-to-maturity Securities [Line Items]
Short-Term	$ 6,035	$ 6,457
Long-Term	64,082	57,511
Municipal Debt Securities [Member]
Schedule of Held-to-maturity Securities [Line Items]
Short-Term	5,539	5,492
Long-Term	35,827	34,495
Federal Home Loan Securities [Member]
Schedule of Held-to-maturity Securities [Line Items]
Long-Term	27,030	22,520
Certificates of Deposit [Member]
Schedule of Held-to-maturity Securities [Line Items]
Short-Term	496	965
Long-Term	$ 1,225	$ 496

Investments - Schedule of Contractual Maturities of Long-Term Investments (Detail) (USD $) In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Investments, Debt and Equity Securities [Abstract]
Due after one year through five years	$ 54,959	$ 41,655
Due after five years through seven years	9,123	15,856
Total	$ 64,082	$ 57,511

Accounts Receivable and Net Revenue - Schedule of Accounts Receivable, Net (Detail) (USD $) In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Receivables [Abstract]
Gross accounts receivable	$ 1,200,958	$ 997,682
Allowance for contractual adjustments and uncollectibles	(848,767)	(712,285)
Accounts receivable, net	$ 352,191	$ 285,397

Accounts Receivable and Net Revenue - Schedule of Net Revenue (Detail) (USD $) In Thousands, unless otherwise specified	3 Months Ended								12 Months Ended
	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Receivables [Abstract]
Gross revenue									$ 7,662,556	$ 6,702,484	$ 5,691,790
Contractual adjustments and uncollectibles									(5,403,437)	(4,695,232)	(3,994,924)
Hospital contract administrative fees									179,794	146,760	119,746
Net revenue	$ 650,525	$ 626,506	$ 595,544	$ 566,338	$ 567,387	$ 554,730	$ 529,180	$ 502,715	$ 2,438,913	$ 2,154,012	$ 1,816,612

Accounts Receivable and Net Revenue - Additional Information (Detail) (USD $) In Thousands, unless otherwise specified	3 Months Ended								12 Months Ended
	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Receivables [Abstract]
Accounts receivable, net	$ 352,191				$ 285,397				$ 352,191	$ 285,397
Net patient service revenue	$ 650,525	$ 626,506	$ 595,544	$ 566,338	$ 567,387	$ 554,730	$ 529,180	$ 502,715	$ 2,438,913	$ 2,154,012	$ 1,816,612

Property and Equipment - Schedule of Property and Equipment (Detail) (USD $) In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Abstract]
Building	$ 22,981	$ 22,981
Land	6,683	6,683
Equipment and other	133,279	117,246
Property and equipment, gross	162,943	146,910
Accumulated depreciation	(96,895)	(86,999)
Property and equipment, net	$ 66,048	$ 59,911

Property and Equipment - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Property, Plant and Equipment [Line Items]
Medical and other equipment held under capital leases	$ 162,943,000	$ 146,910,000
Accumulated depreciation of property and equipment held under capital leases	96,895,000	86,999,000
Recorded depreciation expense	15,900,000	15,500,000	15,800,000
Medical and Other Equipment [Member]
Property, Plant and Equipment [Line Items]
Medical and other equipment held under capital leases	2,400,000	1,400,000
Accumulated depreciation of property and equipment held under capital leases	$ 1,400,000	$ 1,200,000

Business Acquisitions - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014 Company Acquisition	Dec. 31, 2013 Company	Jun. 01, 2014 JointVenture
Business Acquisition [Line Items]
Number of physician group practices acquired	11	11
Business acquisition, total consideration	$ 488,600,000	$ 250,100,000
Cash consideration	479,400,000	236,700,000
Contingent consideration	9,200,000	13,400,000
Number of acquisitions completed	13
Time period for achievement of certain performance measures for payment of contingent consideration, years	5 years
Business acquisition contingent consideration recorded as liability	8,500,000
Business acquisition contingent consideration recorded as equity	700,000
Assumed payment probability of contingent consideration payment	100.00%
Range of the undiscounted amount under contingent consideration agreement, low	0
Range of the undiscounted amount under contingent consideration agreement, high	10,300,000
Contingent consideration decrease in fair value	1,600,000
Contingent consideration payments related to prior-period acquisitions	15,800,000
Contingent consideration payments related to prior-period acquisitions	37,500,000
Number of joint ventures			2
Fair value, contribution credit	7,700,000
Carrying value of goodwill transferred	7,200,000
Fixed assets transferred	500,000
Gain or loss from the joint venture transaction	0
Consolidation method ownership interest in joint method	75.00%
Equity method ownership percentage in joint venture	37.50%		37.50%
Goodwill	2,776,188,000	2,393,731,000
Other intangible assets		29,600,000
Other liabilities		8,100,000
Prior-Period Acquisitions [Member]
Business Acquisition [Line Items]
Contingent consideration	35,300,000
11 Physician Group Practices Acquisition [Member]
Business Acquisition [Line Items]
Goodwill		$ 228,600,000
Minimum [Member]
Business Acquisition [Line Items]
Assumed discount rates for acquisition-date fair value	2.50%
Maximum [Member]
Business Acquisition [Line Items]
Assumed discount rates for acquisition-date fair value	5.30%

Business Acquisitions - Summary of Company's Purchase Allocation Price (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Business Acquisition Purchase Price Allocation [Line Items]
Goodwill	$ 2,776,188,000	$ 2,393,731,000
Other intangible assets		29,600,000
Other long-term liabilities		(8,100,000)
13 Physician Group Practices Acquisition [Member]
Business Acquisition Purchase Price Allocation [Line Items]
Current assets	11,800,000
Property and equipment	3,800,000
Goodwill	389,600,000
Other intangible assets	124,800,000
Current liabilities	(14,400,000)
Deferred income tax liabilities-long-term	(26,300,000)
Other long-term liabilities	(700,000)
Total assets and liabilities	$ 488,600,000

Business Acquisitions - Schedule of Pro Forma Information Combines Consolidated Results of Company and Business Acquisitions (Detail) (USD $) In Thousands, except Per Share data, unless otherwise specified	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Business Combinations [Abstract]
Net revenue	$ 2,590,384	$ 2,494,968
Net income	$ 326,216	$ 301,076
Net income per common share, Basic	$ 3.31	$ 3.04
Net income per common share, Diluted	$ 3.27	$ 2.98
Weighted average common shares, Basic	98,588	99,112
Weighted average common shares, Diluted	99,887	100,969

Goodwill and Other Assets - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill	$ 2,776,188,000	$ 2,393,731,000
Change in goodwill carrying amount	382,500,000	228,100,000
Goodwill deductible for tax purpose	229,300,000
Other intangible assets gross carrying amounts	299,000,000	174,400,000
Accumulated amortization	100,900,000	70,800,000
Amortization expense for existing other intangible assets	30,100,000	24,500,000	15,000,000
Remaining weighted average amortization period of other intangible assets, in years	8 years 8 months 12 days
Weighted average amortization period includes amortization expense related to years beyond 2019	69,100,000
Other assets	37,289,000	25,799,000
Carrying amount of cash surrender value of life insurance	16,000,000	17,100,000
Investments in joint venture	$ 9,500,000

Goodwill and Other Assets - Schedule of Other Assets (Detail) (USD $) In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Goodwill and Intangible Assets Disclosure [Abstract]
Other intangible assets, net	$ 198,136	$ 103,639
Other assets	37,289	25,799
Other assets, net	$ 235,425	$ 129,438

Goodwill and Other Assets - Amortization Expenses for Existing Other Intangible Assets for the Next Five Years (Detail) (USD $) In Thousands, unless otherwise specified	Dec. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense for existing other intangible assets, 2015	$ 36,874
Amortization expense for existing other intangible assets, 2016	30,985
Amortization expense for existing other intangible assets, 2017	24,919
Amortization expense for existing other intangible assets, 2018	20,190
Amortization expense for existing other intangible assets, 2019	$ 16,059

Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Detail) (USD $) In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Payables and Accruals [Abstract]
Accounts payable	$ 32,783	$ 18,605
Accrued salaries and bonuses	231,390	189,439
Accrued payroll taxes and benefits	49,858	43,403
Accrued professional liability	19,718	19,324
Accrued contingent consideration	17,010	19,833
Other accrued expenses	29,899	18,150
Accounts payable and accrued expenses, total	$ 380,658	$ 308,754

- Definition

Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References+ Details

- Definition

Carrying value as of the balance sheet date of obligations incurred through that date and payable arising from transactions not otherwise specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References+ Details

Accounts Payable and Accrued Expenses - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Payables and Accruals [Abstract]
Net increase in accrued salaries and bonuses	$ 42,000,000
Accrued salaries and bonuses	$ 231,390,000	$ 189,439,000

- Definition

+ References+ Details

Accrued Professional Liability - Additional Information (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Payables and Accruals [Abstract]
Total accrued professional liability	$ 168,369,000	$ 158,691,000	$ 137,036,000	$ 122,847,000
Accrued professional liability incurred but loss reserves not reported for claims	120,600,000	110,300,000
Accrued professional liability incurred and loss reserves reported for claims	$ 47,800,000	$ 48,400,000

Accrued Professional Liability - Schedule of Accrued Professional Liability (Detail) (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Payables and Accruals [Abstract]
Balance at beginning of year	$ 158,691	$ 137,036	$ 122,847
Provision (adjustment) for losses related to Current year	39,386	41,235	35,441
Provision (adjustment) for losses related to Prior years	(16,125)	(8,100)	(8,119)
Total provision for losses	23,261	33,135	27,322
Claim payments related to Current year	(293)	(741)	(569)
Claim payments related to Prior years	(13,290)	(10,739)	(12,564)
Total payments	(13,583)	(11,480)	(13,133)
Balance at end of year	$ 168,369	$ 158,691	$ 137,036

Long-Term Debt and Capital Lease Obligations - Additional Information (Detail) (USD $)	0 Months Ended	12 Months Ended
	Oct. 29, 2014	Dec. 31, 2014
Line of Credit Facility [Line Items]
Line of Credit facility, maturity date	Oct. 29, 2019
Line of Credit facility, estimated increase in borrowings		$ 1,800,000,000
Line of credit description		At the Company’s option, borrowings under the Credit Agreement (other than swingline loans) will bear interest at (i) the Alternate Base Rate (defined as the higher of (a) the prime rate, (b) the Federal Funds Rate plus 1/2 of 1.00% and (c) LIBOR for an interest period of one month plus 1.00%) plus an applicable margin rate ranging from 0.125% to 0.750% based on the Company’s consolidated leverage ratio or (ii) the LIBOR rate plus an applicable margin rate ranging from 1.125% to 1.750% based on the Company’s consolidated leverage ratio. Swingline loans will bear interest at the alternate base rate plus the applicable margin.
Line of Credit facility, reduction in the available balance		200,000
Line of Credit facility, available balance		931,800,000
Minimum [Member]
Line of Credit Facility [Line Items]
Commitment fee percentage	0.15%
Maximum [Member]
Line of Credit Facility [Line Items]
Commitment fee percentage	0.30%
Alternate Base Rate [Member]
Line of Credit Facility [Line Items]
Debt instrument, interest rate		1/2 of 1.00%
Alternate Base Rate [Member] \| LIBOR [Member]
Line of Credit Facility [Line Items]
Debt instrument, interest rate		LIBOR for an interest period of one month plus 1.00%
Debt instrument, variable interest rate	1.00%
Applicable Margin Rate [Member] \| LIBOR [Member] \| Minimum [Member]
Line of Credit Facility [Line Items]
Debt instrument, variable interest rate	0.125%
Applicable Margin Rate [Member] \| LIBOR [Member] \| Maximum [Member]
Line of Credit Facility [Line Items]
Debt instrument, variable interest rate	0.75%
Unsecured Revolving Credit Facility [Member]
Line of Credit Facility [Line Items]
Line of Credit facility, borrowing capacity	1,300,000,000
Term Loan Credit Facility [Member]
Line of Credit Facility [Line Items]
Line of Credit facility, borrowing capacity	200,000,000
Swingline Loans [Member]
Line of Credit Facility [Line Items]
Line of Credit facility, borrowing capacity	75,000,000
Letter of Credit [Member]
Line of Credit Facility [Line Items]
Line of Credit facility, borrowing capacity	$ 37,500,000

Long-Term Debt and Capital Lease Obligations - Schedule of Long-Term Debt (Detail) (USD $) In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Debt Instrument [Line Items]
Long-term debt	$ 568,000	$ 27,000
Less: Current portion	(10,000)
Long-term portion	558,000	27,000
Term Loan Credit Facility [Member]
Debt Instrument [Line Items]
Long-term debt	200,000
Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Long-term debt	$ 368,000	$ 27,000

- Definition

The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.

+ References+ Details

- Definition

Carrying amount of long-term debt, net of unamortized discount or premium, including current and noncurrent amounts. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.

+ References+ Details

Long-Term Debt and Capital Lease Obligations - Schedule of Aggregate Annual Maturities of Term Loan (Detail) (USD $) In Thousands, unless otherwise specified	Dec. 31, 2014
Long-term Debt, Fiscal Year Maturity [Abstract]
2015	$ 10,000
2016	10,000
2017	20,000
2018	30,000
2019 and thereafter	$ 130,000

Long-Term Debt and Capital Lease Obligations - Schedule of Capital Lease Obligations (Detail) (USD $) In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Debt Disclosure [Abstract]
Capital lease obligations	$ 1,320	$ 235
Less: Current portion	(465)	(92)
Long-term capital lease obligations	$ 855	$ 143

- Definition

Amount equal to the present value (the principal) at the beginning of the lease term of minimum lease payments during the lease term (excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, together with any profit thereon) net of payments or other amounts applied to the principal, through the balance sheet date and due to be paid more than one year (or one operating cycle, if longer) after the balance sheet date.

+ References+ Details

Long-Term Debt and Capital Lease Obligations - Schedule of Amounts Due Under Terms of Capital Lease Obligations (Detail) (USD $) In Thousands, unless otherwise specified	Dec. 31, 2014
Debt Disclosure [Abstract]
2015	$ 465
2016	414
2017	332
2018	67
2019	$ 42

Income Taxes - Summary of Components of Income Tax Provision (Detail) (USD $) In Thousands, unless otherwise specified	3 Months Ended								12 Months Ended
	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Abstract]
Federal, Current									$ 167,745	$ 134,938	$ 111,940
Federal, Deferred									2,262	14,784	19,814
Federal income tax provision (benefit), Total									170,007	149,722	131,754
State, Current									21,109	17,037	13,980
State, Deferred									297	1,136	1,530
State income tax provision (benefit), Total									21,406	18,173	15,510
Income tax provision (benefit), Total	$ 50,594	$ 51,174	$ 48,944	$ 40,701	$ 44,423	$ 45,198	$ 42,876	$ 35,398	$ 191,413	$ 167,895	$ 147,264

- Definition

Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.

+ References+ Details

- Definition

Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.

+ References+ Details

- Definition

Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.

+ References+ Details

- Definition

Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.

+ References+ Details

Income Taxes - Additional Information (Detail) (USD $)	12 Months Ended
Income Taxes - Additional Information (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Tax Contingency [Line Items]
Effective tax rate	37.63%	37.44%	37.94%
Excess tax benefits related to stock-based awards, which increased the cash flow from financing activities	$ 17,500,000	$ 19,000,000	$ 6,200,000
Net operating loss carryforwards for federal and state tax	29,000,000	16,900,000	14,900,000
Company's total liability for uncertain tax positions	17,165,000	14,902,000	13,072,000	16,165,000
Uncertain tax positions recognized would favorably impact its effective tax rate	16,100,000
Increase in uncertain tax position	2,300,000	1,800,000
Increase (decrease) of interest and penalties	300,000	(600,000)	300,000
Company's accrued liability for interest and penalties related to income tax liabilities	8,700,000	8,400,000
Accounts payable and accrued expenses	25,900,000	23,300,000
Earliest Tax Year [Member]
Income Tax Contingency [Line Items]
Federal and state income tax examinations	2004
Latest Tax Year [Member]
Income Tax Contingency [Line Items]
Federal and state income tax examinations	2013
Minimum [Member]
Income Tax Contingency [Line Items]
Expiration period of operating loss carryforwards	2019
Maximum [Member]
Income Tax Contingency [Line Items]
Expiration period of operating loss carryforwards	2034
Scenario, Forecast [Member]
Income Tax Contingency [Line Items]
Increase in uncertain tax position	4,900,000
Decrease in uncertain tax position	$ 1,700,000

Income Taxes - Schedule of Differences Between Effective Rate and United States Federal Income Tax Statutory Rate (Detail)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Abstract]
Tax at statutory rate	35.00%	35.00%	35.00%
State income tax, net of federal benefit	2.74%	2.63%	2.60%
Non-deductible expenses	0.33%	0.27%	0.36%
Change in accrual estimates relating to uncertain tax positions	(0.59%)	(0.48%)	(0.15%)
Other, net	0.15%	0.02%	0.13%
Income tax provision	37.63%	37.44%	37.94%

Income Taxes - Significant Components of Deferred Income Tax Assets and Liabilities (Detail) (USD $) In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Components Of Deferred Income Tax Assets And Liabilities [Line Items]
Allowance for uncollectible accounts	$ 48,178	$ 42,425
Reserves and accruals	62,708	52,519
Stock-based compensation	14,354	16,457
Net operating loss carryforward	10,933	6,385
Property and equipment	1,524	1,310
Other	1,461	446
Total deferred tax assets	139,158	119,542
Amortization	(214,968)	(162,399)
Accrual to cash adjustment	(38,524)	(37,818)
Other	(192)
Total deferred tax liabilities	(253,684)	(200,217)
Net deferred tax (liability) asset	(114,526)	(80,675)
Total deferred tax assets	(139,158)	(119,542)
Amortization	(214,968)	(162,399)
Accrual to cash adjustment	(38,524)	(37,818)
Other	(192)
Total deferred tax liabilities	(253,684)	(200,217)
Net deferred tax (liability) asset	(114,526)	(80,675)
Total deferred tax liabilities	253,684	200,217
Net deferred tax (liability) asset	(114,526)	(80,675)
Current [Member]
Components Of Deferred Income Tax Assets And Liabilities [Line Items]
Allowance for uncollectible accounts	48,178	42,425
Reserves and accruals	26,066	18,341
Stock-based compensation	8,346	3,628
Net operating loss carryforward	1,504	3,744
Other	583	446
Total deferred tax assets	84,677	68,584
Accrual to cash adjustment	(38,524)	(37,818)
Other	(192)
Total deferred tax liabilities	(38,716)	(37,818)
Net deferred tax (liability) asset	45,961	30,766
Total deferred tax assets	(84,677)	(68,584)
Accrual to cash adjustment	(38,524)	(37,818)
Other	(192)
Total deferred tax liabilities	(38,716)	(37,818)
Net deferred tax (liability) asset	45,961	30,766
Total deferred tax liabilities	38,716	37,818
Net deferred tax (liability) asset	45,961	30,766
Non-Current [Member]
Components Of Deferred Income Tax Assets And Liabilities [Line Items]
Reserves and accruals	36,642	34,178
Stock-based compensation	6,008	12,829
Net operating loss carryforward	9,429	2,641
Property and equipment	1,524	1,310
Other	878
Total deferred tax assets	54,481	50,958
Amortization	(214,968)	(162,399)
Total deferred tax liabilities	(214,968)	(162,399)
Net deferred tax (liability) asset	(160,487)	(111,441)
Total deferred tax assets	(54,481)	(50,958)
Amortization	(214,968)	(162,399)
Total deferred tax liabilities	(214,968)	(162,399)
Net deferred tax (liability) asset	(160,487)	(111,441)
Total deferred tax liabilities	214,968	162,399
Net deferred tax (liability) asset	$ (160,487)	$ (111,441)

Income Taxes - Schedule of Activity Related to Gross Unrecognized Tax Benefits (Detail) (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Abstract]
Balance at beginning of year	$ 14,902	$ 13,072	$ 16,165
Increases related to prior year tax positions	40	338	102
Decreases related to prior year tax positions		(38)
Increases related to current year tax positions	3,750	2,955	2,478
Decreases related to current year tax positions			(3,671)
Decreases related to lapse of statutes of limitations	(1,527)	(1,425)	(2,002)
Balance at end of year	$ 17,165	$ 14,902	$ 13,072

Common and Common Equivalent Shares - Schedule of Calculation of Shares Used in Basic and Diluted Net Income Per Share (Detail) In Thousands, unless otherwise specified	3 Months Ended								12 Months Ended
	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Earnings Per Share [Abstract]
Weighted average shares, Basic	98,066	99,088	98,411	99,076	99,469	99,506	99,116	98,618	98,588	99,112	97,386
Weighted average number of dilutive common share equivalents									1,299	1,857	1,996
Weighted average shares, Diluted	99,129	100,145	99,866	100,696	101,080	101,178	101,098	100,784	99,887	100,969	99,382
Antidilutive securities not included in the diluted net income per common share calculation									1	35	58

- Definition

Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.

+ References+ Details

Stock Incentive Plans and Stock Purchase Plan - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for future grants and awards under Stock Incentive Plans	6,300,000
Stock-based compensation expense related to its stock incentive plans and stock purchase plan	$ 31,700,000	$ 31,300,000	$ 28,400,000
Aggregate fair value of restricted shares, vested	28,200,000	33,300,000	23,000,000
Weighted average grant-date fair value of restricted and deferred stock awards granted	$ 57.73	$ 46.48	$ 30.06
Stock-based compensation cost related to non-vested stock options remaining to be recognized as compensation expense, weighted-average period in years	1 year 4 months 24 days
Unrecognized Compensation Expense related to Nonvested Shares	26,100,000
Aggregate intrinsic value of stock options exercised	38,800,000	35,400,000	18,100,000
Excess tax benefit related to employee stock incentive plans	17,479,000	18,981,000	6,198,000
Cash proceeds received from the exercise of stock options	$ 30,100,000	$ 18,900,000	$ 20,800,000
Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of years over which options become exercisable on a pro rata basis	3 years
Stock Option [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period of options, maximum years	10 years
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of years over which options become exercisable on a pro rata basis	3 years
1996 Non-Qualified Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of market value of common stock at which employees are permitted to purchase	85.00%
Percentage of discount received by participating employees	15.00%
Shares reserved for issuance	335,000
Shares issued under Stock Purchase Plan	260,000

Stock Incentive Plans and Stock Purchase Plan - Schedule of Weighted Average Grant Date Fair Values (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Number of Shares, Non-vested shares at January 1, 2014	1,519,976
Number of Shares, Awarded	529,431
Number of Shares, Forfeited	(33,569)
Number of Shares, Vested	(744,794)
Number of Shares, Non-vested shares at December 31, 2014	1,271,044	1,519,976
Weighted Average Fair Value, Non-vested shares at January 1, 2014	$ 37.78
Weighted Average Fair Value, Awarded	$ 57.73	$ 46.48	$ 30.06
Weighted Average Fair Value, Forfeited	$ 42.19
Weighted Average Fair Value, Vested	$ 37.90
Weighted Average Fair Value, Non-vested shares at December 31, 2013	$ 46.80	$ 37.78

Stock Incentive Plans and Stock Purchase Plan - Schedule of Activity and Certain Other Information Related to Stock Option Awards (Detail) (USD $) In Millions, except Share data, unless otherwise specified	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Number of Shares, Outstanding at January 1, 2014	1,966,170
Number of Shares, Exercised	(1,151,576)
Number of Shares, Forfeited	(500)
Number of Shares, Outstanding at December 31, 2014	814,094	1,966,170
Number of Shares, Exercisable at December 31, 2014	814,094
Weighted Average Exercise Price, Outstanding at January 1, 2014	$ 26.74
Weighted Average Exercise Price, Exercised	$ 26.16
Weighted Average Exercise Price, forfeited	$ 27.72
Weighted Average Exercise Price, Outstanding at December 31, 2014	$ 27.57	$ 26.74
Weighted Average Exercise Price, Exercisable at December 31, 2014	$ 27.57
Weighted Average Remaining Contractual Term (in years), Outstanding at December 31, 2014	3 years 7 months 6 days
Weighted Average Remaining Contractual Term (in years), Exercisable at December 31, 2014	3 years 7 months 6 days
Aggregate Intrinsic Value, Exercised	$ 38.8	$ 35.4	$ 18.1
Aggregate Intrinsic Value, forfeited	0
Aggregate Intrinsic Value, Outstanding at December 31, 2014	31.4
Aggregate Intrinsic Value, Exercisable at December 31, 2014	$ 31.4

Common Stock Repurchase Programs - Additional Information (Detail) (USD $) In Millions, unless otherwise specified	12 Months Ended
	Dec. 31, 2014	Oct. 31, 2014	Dec. 15, 2014 JPMorgan Chase Bank, N.A [Member]	Dec. 17, 2014 Accelerated Share Repurchase (ASR) Agreements [Member] JPMorgan Chase Bank, N.A [Member]
Common Stock [Line Items]
Common stock paid	$ 488.4	$ 600.0		$ 200.0
Common stock shares issued	7.1			2.5
Amount withheld to satisfy minimum statutory tax withholding obligations	1.1
Common stock purchase			$ 200.0

Commitments and Contingencies - Schedule of Future Minimum Lease Payments under Non-Cancelable Operating Leases (Detail) (USD $) In Thousands, unless otherwise specified	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
2015	$ 27,272
2016	21,579
2017	16,894
2018	12,347
2019	7,600
Thereafter	10,928
Total	$ 96,620

Selected Quarterly Financial Information - Summary of Company's Selected Quarterly Financial Information (Detail) (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended								12 Months Ended
	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Quarterly Financial Information Disclosure [Abstract]
Net revenue	$ 650,525	$ 626,506	$ 595,544	$ 566,338	$ 567,387	$ 554,730	$ 529,180	$ 502,715	$ 2,438,913	$ 2,154,012	$ 1,816,612
Practice salaries and benefits	404,345	394,794	372,216	372,040	353,316	346,879	331,922	329,201	1,543,395	1,361,318	1,130,913
Practice supplies and other operating expenses	23,549	21,570	22,466	21,417	24,027	19,445	19,416	19,500	89,002	82,388	71,823
General and administrative expenses	67,641	60,643	60,829	58,414	55,636	54,654	54,601	53,318	247,527	218,209	193,540
Depreciation and amortization	13,903	11,356	10,361	10,370	10,491	10,461	9,870	9,144	45,990	39,966	30,816
Total operating expenses	509,438	488,363	465,872	462,241	443,470	431,439	415,809	411,163	1,925,914	1,701,881	1,427,092
Income from operations	141,087	138,143	129,672	104,097	123,917	123,291	113,371	91,552	512,999	452,131	389,520
Investment income	195	563	335	1,635	526	372	396	402	2,728	1,696	1,896
Interest expense	(3,313)	(2,019)	(2,188)	(1,371)	(1,046)	(1,507)	(1,673)	(1,189)	(8,891)	(5,415)	(3,245)
Equity in earnings of unconsolidated affiliate	905	725	150						1,780
Total non-operating expenses	(2,213)	(731)	(1,703)	264					(4,383)	(3,719)	(1,349)
Income before income taxes	138,874	137,412	127,969	104,361	123,397	122,156	112,094	90,765	508,616	448,412	388,171
Income tax provision	50,594	51,174	48,944	40,701	44,423	45,198	42,876	35,398	191,413	167,895	147,264
Net income	88,280	86,238	79,025	63,660					317,203	280,517	240,907
Net (income) loss attributable to noncontrolling interests	118	(31)	(9)						78
Net income attributable to MEDNAX, Inc.	$ 88,398	$ 86,207	$ 79,016	$ 63,660	$ 78,974	$ 76,958	$ 69,218	$ 55,367	$ 317,281	$ 280,517	$ 240,907
Earnings per share, Basic	$ 0.90	$ 0.87	$ 0.80	$ 0.64	$ 0.79	$ 0.77	$ 0.70	$ 0.56	$ 3.22	$ 2.83	$ 2.47
Earnings per share, Diluted	$ 0.89	$ 0.86	$ 0.79	$ 0.63	$ 0.78	$ 0.76	$ 0.68	$ 0.55	$ 3.18	$ 2.78	$ 2.42
Weighted average shares, Basic	98,066	99,088	98,411	99,076	99,469	99,506	99,116	98,618	98,588	99,112	97,386
Weighted average shares, Diluted	99,129	100,145	99,866	100,696	101,080	101,178	101,098	100,784	99,887	100,969	99,382

Schedule II - Valuation and Qualifying Accounts (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Valuation and Qualifying Accounts [Abstract]
Balance at beginning of year	$ 712,285	$ 624,896	$ 576,030
Amount charged against operating revenue	5,403,437	4,695,232	3,994,924
Accounts receivable contractual adjustments and write-offs (net of recoveries)	(5,266,955)	(4,607,843)	(3,946,058)
Balance at end of year	$ 848,767	$ 712,285	$ 624,896

General - Additional Information (Detail)	12 Months Ended
General - Additional Information (Detail)	Dec. 31, 2014 Business
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of complementary business acquired	2